{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "2fe647729c5efd3ab230a107bef36d9a",
    "title": "Healthcare",
    "source_uri": "2025-08-29/Aug Monthly increasingly prefer stocks with high - quality earnings Industry OverviewAug Monthly increasingly prefer sto_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T23:53:35.970320",
      "extracted_at": "2025-10-26T23:53:35.970329"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 27,
        "successful_pages": 27,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 3,
          "reduction_ratio": 0.07200803212851403
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "c06056e526f18558",
      "text": "Among the 48 healthcare- related stocks, 27 outperformed TOPIX (vs. 22 outperforms in our July report and 29 in June) in the four weeks to 22 Aug. Biopharma once again fell out of favor, while there was a bipolarization of share- price performance by Medtech and Healthcare Services stocks based on confirmation of fundamentals at the earnings results. Heading into 3Q results, we look for quality stocks to outperform more than laggard or low valuations stocks.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "152fde3ffdacafb6",
      "text": "Our Biopharma recommendations of Daiichi Sankyo, Otsuka, and Chugai are based on earnings, catalysts, and valuations. Among Medtech stocks, we like Shimadzu on expectations for an upward revision to FY3/26 earnings guidance, whereas other names like Terumo and Fujifilm remain attractive for their stable earnings prospects. We downgraded Olympus to Neutral on 26 Aug (see report: Down to Neutral: no longer undervalued given weak earnings and reduced visibilities). For Healthcare Services, we believe the strong earnings have already been baked into the share price, so we regard JMDC as attractive. Our Medley recommendation has not yet panned out, but it has become even more undervalued relative to the underlying growth potential. That said, we do not anticipate share- price upside until earnings are confirmed in the Jul- Sep results.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "94d36051e61ed232",
      "text": "- D-Sankyo: I-DXd Ph2 (small cell lung cancer 3L therapy) final analysis presentation at WCLC (7 Sep).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fd5b516b0ecd99de",
      "text": "- Takeda: Oveporexton Ph3 (Narcolepsy Type 1) presentation at World Sleep Conference (8 Sep).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7591ceae2a912d7b",
      "text": "- Chugai: Orforglipron Ph3 (obesity) presentation at EASD (17 Sep).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "903b4a39d52b9f60",
      "text": "- Kyowa Kirin: Rocatinlimab Ph3 (ROCKET-Ascent) data disclosure (Sep-Dec).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b77b787acc6a5b52",
      "text": "- Eisai: US approval for Leqembi (Alzheimer's disease) subcutaneous injection (SC-AI) maintenance therapy (31 Aug).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "33662e3c29a13609",
      "text": "- Shimadzu: information briefing on Analytical & Measurement Instruments business (5 Sep).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3f1733bf68a868d7",
      "text": "- Fujifilm: Tour of US Bio CDMO facility (22 Sep).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a3ed054e7dffa44c",
      "text": "\\(>>\\) Employed by a non- US affiliate of BofAS and is not registered/qualified as a research analyst under the FINRA rules.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c8cad0b743cb87f9",
      "text": "Refer to 'Other Important Disclosures' for information on certain BofAS Securities entities that take responsibility for the information herein in particular jurisdictions.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7c4acbc3e23eeacf",
      "text": "BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c014d4b1ed82be3c",
      "text": "Refer to important disclosures on page 25 to 27. Analyst Certification on page 21. Price Objective Basis/Risk on page 15.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e098bbdb71b29734",
      "text": "Equity Japan Healthcare",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6286050dd7aa8bb9",
      "text": "Exhibit 1: Related stocks Ratings and share price (Â¥, as of 8/29)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b2eba3d6170911cd",
      "text": "TickerNameRatin gPricePODaiichiSankyoBuy3,5295,6004578Otsuka HDBuy7,76610,4004502TakedaBuy4,4215,5004151Kyowa KirinBuy2,5453,2004507ShionogiBuy2,5503,0004536SantenBuy1,5632,1004565NxeraBuy9251,2004519ChugaiNtrl6,5097,2004503AstellasNtrl1,6201,7004528OnoU/P1,6571,4004523EisaiU/P4,5383,8004483JMDCBuy4,1625,0004480MedleyBuy2,4824,1004543TerumoBuy2,6643,4004887Sawai GHDBuy1,8742,2007701ShimadzuBuy3,6224,3006869SysmexBuy1,8682,6007733OlympusNtrl1,7231,8202413M3Ntrl2,1862,3207747Asahi IntecNtrl2,5362,8004901Fujifilm HDNtrl3,5113,9102175SMSU/P1,5831,5009627Ain HDU/P6,1145,1007459Medipal HDU/P2,6142,5006523PHC HDU/P9871,010OTSKYOtsuka HDBuy26.635.9TAKTakedaBuy15.019.0DaiichiDSNKYSankyoBuy24.538.6SGIYOShionogiBuy8.710.3FUJIYFujifilm HDNtrl12.013.5ALPMYAstellasNtrl11.111.7",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "41337cc1619a0e7f",
      "text": "Source: BofA Global Research. Please see the last page for ADR prices. Ntrl: Neutral, U/P: Underperform BofA GLOBAL RESEARCH",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c32c6cb03327018c",
      "text": "Share- price performance, stock selection 3",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dc3b537b0b73cc22",
      "text": "Stock selection in Sep 4",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "48b3947596b22d67",
      "text": "Healthcare Services 6",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5ec9dfa0b59ff096",
      "text": "Events and medical conference calendar 7",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ba9b992bda49495d",
      "text": "Overseas companies linked to our stocks 8",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1935916eeeacecf4",
      "text": "Healthcare monthly statistics 9",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fd8dfcb87e54f47a",
      "text": "Medical expenditure 9",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "49a3e199425e6fce",
      "text": "Trends by subsector 10",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5b8c62d940322eee",
      "text": "Appendix: Share- price performance 11",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "49d304546f758cae",
      "text": "In the four weeks to 22 Aug, the TSE Pharmaceutical Index \\((- 1\\%)\\) underperformed TOPIX \\((+2\\%)\\) , but 27 of the 48 healthcare- related stocks outperformed TOPIX (vs. 22 outperformers in our July report and 29 in June). While Biopharmaceutical stocks remained out of favor, small and medium- cap Healthcare Services stocks with strong earnings drove the sector. As this was the month of earnings announcements, share prices reacted in line with fundamentals. Our recommendations last month were Daiichi Sankyo, Otsuka, Chugai, Shimadzu, Sysmex, and Terumo; Otsuka and Shimadzu performed strongly, but Chugai and Sysmex disappointed.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "8241ac199a646971",
      "text": "Exhibit 2: TOPIX Pharma index vs TOPIX Pharma index underperformed TOPIX again",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b4ac031c760f1b58",
      "text": "Source: Bloomberg, compiled by BofA Global Research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3bc6daf80f84ef28",
      "text": "Exhibit 3: Pharma sector weight in TOPIX Pharma sector proportion (vs TOPIX market cap) declined below \\(5\\%\\)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a880445b153c7cfd",
      "text": "Source: Bloomberg, compiled by BofA Global Research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d168658eb4fed9f5",
      "text": "Universe 49 stocksUpDown1Hogy33.3%1Sysmex2SNBL20.6%2Chugai3Amvis19.6%3Medley4M318.8%4Santen5Astellas14.6%5Towa6Otsuka14.3%6N.Koden7Fujifilm13.6%7Olympus8PHC13.3%8Sawai9Eisai11.9%9Tryt10MDV11.9%10Medpeer11JMDC10.6%11MSNW12Nipro10.4%12N.Shinvaku13Shimadzu9.8%13Shionogi14Qol9.7%14Tsuruha15Toho9.0%15SMS",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "fbc13721e7df3f0e",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2ae216207f393d02",
      "text": "Universe 49 stocksUpDown1N.chozai21.6%1Amvis2Tryt94.7%2Nxera3M357.3%3D.Sankyo4Sugi57.0%4Olympus5Qol48.5%5Sysmex6SNBL44.4%6SMS7Tsuruha31.6%7Ono8HUG30.6%8Eisai9Welcia29.1%9Shimadzu10Hogy21.4%10Medley11Nipro18.5%11K.Kirin12Ain18.1%12N.Koden13Toho17.5%13Santen14Shionogi16.4%14Chugai15TOPIX15.5%15PHC",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f5573c73fb6dfb9c",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "237cfed3f729a373",
      "text": "BofA GLOBAL RESEARCH",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "6240df3c21309fdc",
      "text": "We regard Daiichi Sankyo and Otsuka as attractive based on solid earnings, catalysts, and valuations. For Daiichi Sankyo, our focus is on the 7 Sep WCLC presentation of the final analysis of the pivotal study (IDate- Lung01: 3L therapy for small cell lung cancer) for I- DXd, the third candidate to emerge from the company's proprietary antibody- drug conjugate (ADC) platform. Promising data have already been released, and we look for disclosure of more detailed data to again underscore D- Sankyo's ADC technology. We look for 2H catalysts - i.e., US approval of siberpenlimab and US filings for centanafadine and zipalertinib - to boost Otsuka's share price. Although we rate Chugai Neutral due to its high valuations, we need to scrutinize Ph3 (ATTAIN- 1, ATTAIN- 2) results of oral GLP- 1 orforglipron, which is licensed to Eli Lilly. Orforglipron demonstrated superior weight reduction for obese patients with type 2 diabetes over competing compounds, including already commercialized drugs, but the rate of weight reduction appears to be inferior for obese patients without diabetes. An important consideration in forecasting market share for GLP- 1R agonists is the impact of GI adverse events on oral medication compliance.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b0e4a416c82282e6",
      "text": "We also need to be mindful of the external environment facing the sector. The environment is gradually stabilizing as the broad outline for US tariff measures become clear. However, letters have been sent to companies regarding the Executive Order to lower drug prices - i.e., Most Favored Nation (MFN) treatment with end- Sep set as the deadline for responses. The impact of MFN policy remains unclear, so uncertainty persists. Accordingly, we await guidance on what drugs will be covered and on the price levels.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c723e8ad707f66f2",
      "text": "Two Medtech stocks we like are Terumo (stable earnings prospects) and Shimadzu (expectations for an upward guidance revision). Sysmex's earnings results were disappointing and there is still a risk of a downward revision to guidance, but the share price has declined so much that it looks undervalued. Key themes for Medtech stocks are market trends in North America and China. Recurring demand (e.g., surgeries) is robust, but sluggish capex- related demand persists. The key point for capex- oriented stocks is market cultivation with new products. Olympus looks to start local production and marketing of GI endoscopes in China through a newly established factory, while Shimadzu aims to launch new products in North America and Sysmex is focused on expanding its product line- up through business collaborations and M&A. We downgraded Olympus to Neutral on 26 Aug (see report: Down to Neutral: no longer undervalued given weak earnings and reduced visibilities).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d8d25728d60b9787",
      "text": "Among Healthcare Services stocks, we prefer JMDC on resumed growth of the mainstay business, though Medley also looks interesting as the share price fell sharply following the unexpected decline in profits, so it could present share- price upside if Jul- Sep results confirm a recovery. Healthcare Services businesses are mainly centered on the domestic market, so the April 2026 healthcare reforms will be a key issue. M3, Medley, and JMDC are positioned to benefit from the full- scale government promotion of medical DX. Reform measures, such as the NHI drug revisions, dispensing fee revisions, and promotion of generic drugs will be used to fund higher wages in the medical and welfare industries. The reform measures will likely be negative for dispensing pharmacies and pharmaceutical wholesalers but positive for generic drug manufacturers.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4895bce09446541b",
      "text": "The Apr- Jun results revealed that Otsuka and Daiichi Sankyo maintained robust earnings (Otsuka revised up full- year earnings guidance), while Astellas and Eisai confirmed a bottoming out of earnings in line with guidance. In contrast, the earnings results for Chugai and Santen were disappointing. Chugai's sluggish 1H earnings results were attributed to delayed shipments of Hemlibra (hemophilia A), but the termination of five development projects, including mid- sized molecule drug LUNA18, was seen as negative. Santen's depressed 1Q results were due to excess distribution inventories, but production of Diquas LX has already resumed, and management expected earnings to recover from 2H. Takeda also saw a marked slowdown in growth of existing drugs (Entyvio and plasma derived therapies) but we anticipate a recovery from 2Q.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1e7fe73f6f79623a",
      "text": "Exhibit 6: Quarterly earnings review for healthcare Consensus estimates vs actual (Apr-Jun)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "fc204c32a2ebd348",
      "text": "mn JPYConsensusActualGap vs consensusSalesCore OPSalesYoYvs FYcOFCore OPYoYvs FYcOFSalesBiopharma4568D-SankyoQ1463,30079,900474,5979%24%96,30032%28%4578Otsuka HoldingsQ2597,200116,100597,9261%25%119,500-4%30%6M1,180,000239,0001,180,7666%50%239,20012%60%4151Kyowa KirinQ2128,80026,300125,929-1%26%26,400-1%33%6M233,50034,900230,654-1%48%35,000-21%44%4502TakedaQ11,161,800306,6001,106,685-8%24%321,800-16%28%4536SantenQ172,70013,60068,737-8%23%9,700-39%18%4507ShionogiQ1104,40030,60099,7812%19%35,10025%20%4565NxeraQ2N/AN/A8,4504%-989-53%-6MN/AN/A15,09419%-364-69%-4519ChugaiQ2294,400146,500290,005-8%24%132,500-17%23%6M582,900286,000578,4645%49%272,0004%48%4503AstellasQ1468,50094,500505,7947%26%142,30061%35%4528Ono Pharm.Q1118,70030,700127,5368%26%31,600-10%28%4523EisaiQ1191,20013,600202,6517%26%20,70055%38%",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "aa7e1d57ae306897",
      "text": "Source: BofA Global Research and Visible Alpha consensus. FY CoE: Full year Company estimates.Otsuka shows Business profit, Shionogi and Eisai show OP.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c3d701e4b0562bdb",
      "text": "In the Medtech space, margin improvement by Terumo (4543), Fujifilm (4901), Asahi Intec (7747), and PHC Holdings (6523) was well received by investors. Although we expect consensus profit to increase for each of them, we do not see upward revisions to full- year guidance when the companies report 2Q results. We believe Shimadzu (7701) will likely revise up full- year earnings guidance when it reports 2Q results given the strong fundamentals, but do not anticipate an adequate share- price reaction. On the other hand, Sysmex (6869) and Olympus (7733) revised down guidance when reporting 1Q results but even the revised guidance is far from certain, so we note the potential for a downward revision to full- year earnings guidance when 2Q results are reported.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c497681117d7dfc1",
      "text": "Exhibit 7:Quarterly earnings review for healthcare Consensus estimates vs actual (Apr-Jun)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9b4d970e245d7a70",
      "text": "mn JPYConsensusActualGap vs consensusSalesHighestLowestOPHighestLowestSalesYoYvs FYCoEOPYoYvs FYCoEMedtech7733OlympusQ1229,265237,600218,60026,39034,31220,603206,512-12%21%16,351-41%4543TerumoQ1262,556268,100258,00047,17750,00042,845259,9651%25%55,88525%6869SysmexQ1117,435121,900113,40017,96529,50022,220105,731-6%20%10,628-37%7747Asahi IntecQ427,96729,14027,1833,57310,5007,46928,2105%24%4,36476%12M120,025120,955118,99830,07936,21533,184120,02512%101%30,07936%6523PHC HDQ186,54290,57684,5001,8077,0001,62383,856-2%23%3,85383%4901FujifilmQ1758,524766,800748,00069,55283,67072,500749,4820%23%75,29121%7701ShimadzuQ1117,770120,700112,90012,27119,80017,007118,3701%23%12,18411%",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "bef5e737815f3673",
      "text": "Source: BofA Global Research and Bloomberg consensus. FY CoE: Full year Company estimates.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "7f748d21f4ecf53e",
      "text": "Among Healthcare Services stocks, M3 (2413) and JMDC (4483) stand out for their strong profit progression, whereas the unexpected profit decline reported by Medley (4480) was disappointing. The main change that affects our earnings estimate assumptions over the next 2- 3 years is resumed growth of JMDC's Health Big Data business. We still need to confirm the sustainability of M3's growth and look for Medley to stage a recovery from Jul- Sep, so we see no reason to change our investment ratings.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6d8166e0248a659c",
      "text": "There were no major movements by other stocks, although Sawai Group Holdings (4887, Buy) faces a new issue of insufficient production volume. The impact on FY3/26 earnings is likely minimal, but increased production capacity is essential for expected growth from FY3/27 and beyond, so we will be monitoring developments from 2H.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "40569ce6f416d56a",
      "text": "Exhibit 8:Quarterly earnings review for healthcare Consensus estimates vs actual (Apr-Jun)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9f485a65c8c5f502",
      "text": "mn JPYConsensusActualGap vs consensusSalesHighestLowestOPHighestLowestSalesYoYvs FYCoEOPYoYvs FYCoEHigh growth healthcare service2413M3Q185,55787,60083,00017,79017,00013,62086,20034%24%18,73516%4483JMDCQ19,74710,0809,1801,3302,8002,20010,72532%21%1,55249%2175SMSQ119,17119,70618,7473,5251,08412518,6727%28%3,61621%4480MedleyQ211,17612,09010,3332,3529219410,32518%26%1,582-21%6M18,46520,23018,4731,4619,0618,23418,46526%46%1,461-35%Other healthcare service7459Medipal HDQ1935,127938,015930,90012,89813,1949,307945,1594%25%14,0536%4887Sawai GHDQ148,24349,61746,9207,0978,4905,84249,51112%25%6,97915%9627Ain HDQ1122,931126,500117,3563,9514,5003,500122,93119%24%3,95143%",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "b645a473030ad756",
      "text": "Source: BofA Global Research and Bloomberg consensus. FY CoE: Full year Company estimates.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6f812f2189107e70",
      "text": "BofA GLOBAL RESEARCH",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "53134a6282b98f7e",
      "text": "mn JPYConsensusActualGap vs consensusSalesHighestLowestOPHighestLowestSalesYoYvs FYCoEOPYoYvs FYCoEHigh growth healthcare service2413M3Q185,55787,60083,00017,79017,00013,62086,20034%24%18,73516%4483JMDCQ19,74710,0809,1801,3302,8002,20010,72532%21%1,55249%2175SMSQ119,17119,70618,7473,5251,08412518,6727%28%3,61621%4480MedleyQ211,17612,09010,3332,3529219410,32518%26%1,582-21%6M18,46520,23018,4731,4619,0618,23418,46526%46%1,461-35%Other healthcare service7459Medipal HDQ1935,127938,015930,90012,89813,1949,307945,1594%25%14,0536%4887Sawai GHDQ148,24349,61746,9207,0978,4905,84249,51112%25%6,97915%9627Ain HDQ1122,931126,500117,3563,9514,5003,500122,93119%24%3,95143%",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3e800efc523683a0",
      "text": "Key products development, medium-term business plan schedule, etc.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "57e6f20c1231be58",
      "text": "CompanyEventRemarksJulOtsukaAdvisory Committee for Rexulti (PTSD)Rexulti (Otsuka)JulTakedaTLR of overpoetxin P3 (Narcolepsy type 1)oveporetxon (Takeda)AugChugaiTLR of orofiglipron P3 (Obesity)orofiglipron (Chugai)AugAstellasTLR of Padcev P3 (MIBC)Padcev (Astellas)AugEisaiPDUFA date of Leqembi (SC maintenance)Leqembi (Eisai)Aug-SepKyowaKirinTLR of ROCKET-Ascend (long-term data)rocatinlimab (KyowaKirin)Aug-SepDaiichi SankyoTLR of TROPION-Breast02 (1L TNBC)Datroway (Daiichi Sankyo)Aug-SepDaiichi SankyoTLR of DESTINY-Lung04 (1L HER2 mut NSCLC)Enhertu (Daiichi Sankyo)Aug-SepAstellasTLR of Vyloy P2 (Pancreatic cancer)Vyloy (Astellas)SepDaiichi SankyoData presentation of iDecate-Lung01 at WCLC (3L SCLC)I-DXd (Daiichi Sankyo)SepTakedaData presentation of overpoetxin P3 (NT1) at World Sleepoveporetxon (Takeda)SepChugaiData presentation of orofiglipron P3 (Obesity) at EASDorofiglipron (Chugai)OctDaiichi SankyoDS-3939 P1/2 data presentation at ESMODS-3939 (Daiichi Sankyo)OctAstellasASP2138 initial data presentation at ESMOASP2138 (Astellas)Oct-DecTakedaTLR of zascotinib P3 (Psoriasis vs Otezla)zascotinib (Takeda)Oct-DecOtsukaUS accelerated approval of sibeprenlimab (IgAN)sibeprenlimab (Otsuka)Oct-DecOtsukaUS filing of zipalertinib (EGFR exon20 NSCLC)zipalertinib (Otsuka)Oct-DecOtsukaUS filing of cenatanafadine (ADHD)centanafadine (Otsuka)Oct-DecTakedaUS filing of rusfertide P3 (Polycythemia vera)rusfertide (Takeda)Oct-DecChugaiFiling of orofiglipron P3 (Obesity)orofiglipron (Chugai)Oct-DecOnoUS filing of tirabrutinib (PCNSL)tirabrutinib (Ono)Oct-MarShionogiTLR of zatoimlast P2/3 (FXS)zatoimlast (Shionogi)Oct-MarDaiichi SankyoTLR of DESTINY-Breast05 (non-pCR adj. HER2+BC)Enhertu (Daiichi Sankyo)Jan-JunDaiichi SankyoTLR of AVANZAR (1L QCS-NMR, non-SQ NSCLC)Datroway (Daiichi Sankyo)Jan-JunKyowaKirinUS filing of rocatiniblam (atopic dermatitis)rocatinlimab (KyowaKirin)Jan-JunTakedaUS filing of overpoetxin (Narcolepsy type 1)oveporetxon (Takeda)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "aca9c24cd5cbe827",
      "text": "Source: BofA Global Research",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "94b1711b646b8d4f",
      "text": "BofA GLOBAL RESEARCH",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0584c8a5d7133c48",
      "text": "Key medical conferences and related companies (Jul-Dec)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a2a65d4a500c3454",
      "text": "DateAbb.ConferenceRemarksJul 27-31AAICAlzheimer's Association International ConferenceEisai, SysmexAug 29-Sep 1ESCEuropean Society of CardiologySep 6-9WCLCWorld Conference on Lung CancerDaiichi SankyoSep 15-19EASDEuropean Association for the Study of DiabetesChugaiSep 17-20EADVEuropean Academy of Dermatology and VenereologyKyowa KirinSep 24-26ECTRIMSEuropean Committee for Treatment and Research in Multiple SclerosisSep 27-Oct 1ERSEuropean Respiratory Society CongressOct 17-21ESMOEuropean Society for Medical Oncology CongressDaiichi Sankyo, AstellasOct 18-20AAOAmerican Academy of OphthalmologyAstellasOct 22-25NAMSThe North American Menopause SocietyAstellasOct 23-25CCTComplex Cardiovascular TherapeuticsAsahi IntecOct 25-28TCTTranscatheter Cardiovascular TherapeuticsOtsuka HD, TerumoNov 5-9ASNAmerican Society of NephrologyOtsuka, TakedaNov 6-10ACAAIAmerican College of Allergy Asthma and ImmunologyKyowa KirinNov 8-10AHAAmerican Heart AssociationOtsuka HD, TerumoDec 1-4CTADThe Clinical Trials on Alzheimer's disease conferenceEisaiDec 6-9ASHAmerican Society of HematologyChugai, TakedaDec 9-12SABCSSan Antonio Breast Cancer SymposiumDaiichi Sankyo",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "91a1437ec17e6d1c",
      "text": "Source: Conference websites",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "70a24006cc77d122",
      "text": "BofA GLOBAL RESEARCH",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "de02c7841138e59d",
      "text": "**Exhibit 11: Related overseas companies**",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "72892a0fc5707dce",
      "text": "Summary of key competitions and alliances with overseas companies",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "338b7258b641f763",
      "text": "CompanyBiopharmaProductRelated overseas company/productsRelationshipRemarksDaiichi SankyoEnhertu, Dato-DXdAstraZenecaDevelopment & CC*HER3-DXd, DS-6300, DS-7000MerckDevelopment & CC*Enhertu, Dato-DXdGilead/ TrodelvyCompetitorCompete vs Enhertu in HER2-low BC, Dato-DXd in HER2-low BC/NSCLCDS-7300MacroGenics/ MGC018CompetitorMGC018's Ph1/2 will end in Mar 2023ChugaiRoche ProductsRocheParent/subsidiaryHemlibraNovo Nordisk/ mim8CompetitorPh3 will be completed in May 2024HemlibraSanofi/ efanesoctocog alfaCompetitorUS approval (Feb 2023)OWL833(LY-3502970)Eli LillyLicensed outP2 data readout in ADA (-14.7% weight loss at 36w)OWL833(LY-3502970)Novo Nordisk/ amycretinCompetitoramycretin showed promising early efficacy data in P1Kyowa KirinCrysvitaUltragenyxCCKK will own commercial rights in the US from May 2023KHK4083(rocatinlimab)AmgenDevelopment & CCSeven Ph3 study designs disclosedKHK4083(rocatinlimab)Sanofi/ DupixentCompetitorDupixent sales has reached &gt;$20bnShionogiHIV productsGSK/ HIV productsJoint investmentWe focus on sales trend of GabenuvaHIV productsGilead/ HIV productsCompetitorCautious about Biktarvy's sales trendEisaiLeqembiBiogenDevelopment & CCTraditional approval and Medicare coverage started in USLeqembiRoche/ gantenerumabCompetitorPrimary endpoint did not meet in P3LeqembiEli Lilly/ donanemabCompetitorAdcom showed positive opinion in June 2024Morab-202Bristol Myers SquibDevelopment & CCTakedaPDT businessCSLCompetitorPDT businessGrifols SACompetitorAstellasPadcevSeagenCCKeytruda combo granted accelerated approval for 1L mUC (Apr 2023)XtandiPfizerCCCautious about US sales trendelinzanetantBayerCompetitorAchieved primary endpoint in two Phase 3 studiesOtsukaAbilify MaintenaLundbeckCCPluvictoNovartisLicensed outMarket expansion based on 2L mCRPC data. Exp'd RR** up to 18%.KisqaliNovartisLicensed outMarket expansion based on early BC data. Exp'd RR up to 4%.RDNMedtronicCompetitorNxeraPivlaz, daridorexantIdorsia (JP/Asia)AcquisitionIdorsia (JP/Asia) acquisition including development pipeline (Pivlaz, daridorexant etc.)PF-06954522Pfizer/PF-06954522Licensed outPfizer licensed-in PF-06954522 after discontinuing lotiglipron developmentLotiglipronEli Lilly/ orforglipronCompetitorP2 data readout in ADA (-14.7% weight loss at 36w)MedtechIndustryJ&J, Boston Scientific, StrykerSurgical procedure volume / hospital CapEx trend indicatorAsahi IntecVarious productsBoston ScientificCompetitor, CCGuidewiresAbbott LaboratoriesCompetitorOlympusDisposable endoscopeBoston Scientific, AmbuCompetitorTerumoPDT businessCSLCCNew growth areasJ&J, Stryker, PenumbraCompetitorTerumo accelerates growth investment in growing TARDN businessMedtronic, Otsuka HDCompetitorPotential partnership with Otsuka's RDNSysmexChina businessMindrayCompetitorSurgical robotIntuitive SurgicalCompetitorIVD businessAbbott, DanaherCompetitorRoche, Siemens HealthineersCompetitor,CCFujifilmMedical SystemsPhilips, Siemens HealthineersCompetitorGE HealthcareCCCDMOLonza, Samsung Bio,Wuxi Bio, CatalentCompetitorBruker, Danaher,Thermo Fisher ScientificCompetitorShimazduAMIAgilent, Waters,CompetitorRoche, DexCom, mbecta,Tandem Diabetes CareCompetitorDiabetes ManagementInsuletCC",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2419a3f6abf34987",
      "text": "**Source**: BofA Global Research. *CC: Commercial Collaboration, **RR: Royalty Rate",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6725db1ab1719fab",
      "text": "Exhibit 12: National Medical Spending Medical, Dispensing Pharmacy, Home medical nursing",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "5473813d2367f43d",
      "text": "Exhibit 14: National Medical Spending Spending by medical specialties",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ea13be98b8e2deb0",
      "text": "Exhibit 13: National Medical Spending Hospital, Clinics, Pre-school children, Elderlies",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "35185444ea7bf866",
      "text": "Exhibit 15: National Medical Spending Spending by medical specialties",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "d9bf3b750a880e8c",
      "text": "We show recent trends by subsector based on monthly data provided by the Ministry of Health, Labour and Welfare (MHLW), industry groups, and each company.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "0abaae8d2fb957b3",
      "text": "Exhibit 16: Patient trend In-patient and Out-patient",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b2a91a4e2b63b1b3",
      "text": "Exhibit 17: Pharmaceutical market OTC, Prescription and Generic drugs",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "e466469f6bd164c6",
      "text": "Source: Crecon & Research, Kyokai-kempo",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "2e23920914cc3b08",
      "text": "Exhibit 18: Dispensing pharmacy market Total market, Rx volume and price, DgS market",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a7a5a5a0b4fd5230",
      "text": "Exhibit 19: Major dispensing pharmacy companies Monthly sales trend of public five companies",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "d86263b5100ab05e",
      "text": "Medical spending, medical supply, dispensing pharmacies and generic drug industry",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "75bdba303947a1e1",
      "text": "24/624/724/824/924/1024/1124/1225/125/225/325/425/525/625/7MHLW National Healthcare ExpenditureMedical spending-1.6%4.8%-0.5%-1.1%2.5%1.8%3.3%2.9%-1.7%Medical-2.0%4.0%1.6%1.9%3.5%3.3%4.2%2.7%-1.8%Dental0.9%7.2%2.8%2.5%4.6%5.4%1.8%3.0%1.7%Dispensing pharmacies-2.0%5.9%-1.9%-3.1%3.6%2.1%4.2%2.8%-3.8%Home medical nursing15.1%22.7%19.2%20.7%18.2%18.5%18.3%16.1%14.3%Medical spending, Adj.0.9%1.7%0.4%0.7%0.9%1.8%2.9%2.1%1.5%Hospital-1.0%5.3%0.5%0.6%2.7%1.8%3.8%4.1%0.2%Clinics-4.8%0.6%-4.6%-6.6%-0.9%-0.6%0.9%-1.0%-6.2%-75 years old-3.8%2.3%-2.6%-3.6%0.7%0.2%3.9%0.7%-4.2%Employee insurance-2.0%3.0%-0.9%-2.9%2.3%2.7%-1.9%2.4%-2.7%Government-run insurance-6.3%1.3%-5.1%-4.7%-1.7%-3.5%2.1%-1.8%-6.4%Preschool children-18.0%-12.1%-8.7%-10.4%-8.6%-5.2%1.9%-3.1%-5.5%75+ years old1.3%8.4%2.1%2.1%5.1%4.0%5.5%6.0%1.5%Medical supplyTotal facilities-0.6%-0.6%-0.6%-0. 6%-0.6%-0.6%- 0.6%-0.6%-0.6%-0.6%0.5%-0.5%Hospital YoY-0.8%-0.8%-0.8%-0. 8%-0.8%-0.8%- 0.8%-0.8%-0.8%-0.7%-0.7%-0.7%Clinics YoY-0.2%-0.2%-0.2%-0.1%-0.1%-0.1%-0,1%-0.2%-0.1%0.1%0.1%0.1%Dental office YoY-1.2%-1.2%-1.2%-1. 2%-1.2%-1.2%- 1.3%-1.3%-1.3%-1.3%1.4%50.0%Total beds YoY-1.3%-1.3%-1.3%-1.2%-1.3%-1.2%-1,3%-1.2%-1.2%-1.2%5.0%Hospital bed YoY-1.1%-1.1%-1.1%-1.0%-1.0%-1.0%-1,1%-1.0%-1.0%- 1.0%-0.9%Clinics bed YoY-0.7%-0.6%-0.7%-0.5%-0.6%-0.7%-0,7%-0.7%-0.7%-0.8%-0.8%-0.8%Long-term bed YoY-2.4%-2.5%-2.4%-2.4%-2.2%-2.1%-2.2%-2.0%-1.9%-1.6%-1.2%-1.1%Inpatient YoY0.2%0.9%0.1%-0.4%-0.1%-0.2%0.7%1.6%1.2%1.1%0.8%0.0%Outpatient YoY-7.1%4.0%-4.8%-4.1%0.6%-2.7%-0.3%0.8%-2.0%-0.9%-0.9%-3.6%Length of stay YoY0.8%-5.8%-0.8%-1.5%-5.0%-3.4%-3.9%-3.6%-3.0%-3.0%-2.3%0.0%Bed utilization YoY-0.2%pt2.0%pt-1.5%pt2.1%pt0.5%pt-1.9%pt1.9%pt0.7%pt1.1%pt2.6%pt1.2%pt-1.2%ptDispensing Pharmacy marketDP market, YoY-2.0%5.9%-1.9%-3.1%3.6%2.1%4.2%2.8%-3.8%Number of Rx, YoY-3.2%4.1%-1.1%-3.2%1.7%2.6%4.8%2.2%-4.2%Rx unit price, YoY1.2%1.7%-0.8%0.1%1.9%-0.6%-0.6%0.6%0.4%METI: DgS Rx drugs sales5.4%11.1%8.4%5.6%12.8%12.0%12.0%14.0%6.0%11.8%14.3%14.8%13.9%Major companies, DP salesAin3.0%12.2%3.7%3.7%12.0%7.4%8.8%9.3%2.6%8.1%10.9%10.9%16.3%13.0%Qol1.1%9.1%2.0%1.0%7.2%4.0%5.8%4.5%-3.0%3.8%4.4%2.9%3.8%1.0%MSNW0.8%11.8%1.4%2.6%8.0%4.5%6.6%6.7%-0.9%6.1%4.5%3.5%5.4%Sugi14.1%11.7%13.6%8.9%11.3%12.8%13.8%11.6%7.2%10.9%10.8%9.6%6.9%7.5%Welcia3.7%11.5%5.7%3.0%11.6%7.9%9.2%8.7%2.2%7.3%9.5%10.2%9.5%6.7%Matsu-Coco-1.8%5.1%-0.4%-2.7%4.8%4.2%4.3%3.2%-1.3%2.4%4.3%3.2%3.4%2.0%Same store salesAin0.8%9.4%2.8%0.7%7.9%3.3%4.5%4.9%-1.4%3.8%7.1%3.8%9.8%7.0%MSNW-2.9%7.1%-3.3%-1.7%3.5%0.0%1.9%1.6%-5.1%1.1%2.2%1.1%3.7%Sugi6.9%4.6%7.4%2.8%5.4%6.7%7.8%5.9%2.3%6.6%6.2%4.7%4.7%5.2%Welcia3.7%11.5%5.7%3.0%11.6%7.9%9.2%8.7%2.2%7.3%9.5%10.2%9.5%6.7%Same store Rx volumeAin-3.1%5.6%-1.5%-2.4%3.4%1.1%3.3%3.4%-4.0%1.9%0.9%-1.6%2.3%-1.7%MSNW-5.5%3.1%-3.4%-4.3%0.5%-0.3%2.1%0.3%-5.7%-0.2%-0.5%-3.4%-0.1%Rx drug market, Crecon ResearchPrescription drug-5.5%9.6%-3.6%-0.4%6.3%3.3%7.3%3.8%-5.1%5.2%1.2%0.5%8.0%OTC drug-3.1%0.6%-6.1%-5.2%0.4%-2.6%3.0%6.3%-4.2%-1.4%4.0%-2.3%0.6%Generic market shareMHLW value base18.8%18.3%18.2%18.7%20.1%20.4%20.1%20.3%21.0%MHLW volume base86.0%86.2%86.4%86.6%90.1%90.6%90.8%90.5%90.6%Kyokai Kempo, total84.6%84.8%85.0%85.2%88.4%89.0%89.3%89.0%89.1%89.1%Kempo-ren, total86.0%86.2%86.4%86.6%90.1%90.6%90.8%90.5%",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "cf457c04e4aa6090",
      "text": "Source: BofA Global Research from various sources.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "555fa01f73492416",
      "text": "Exhibit 21: Performance comp - biopharma stocks Last 52 weeks performance",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "3b4f5603b1ce6a1e",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "cf7590b4df46bf64",
      "text": "Exhibit 22: Performance comp - medtech stocks Last 52 weeks performance",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "de5dd90b1a4258b4",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f1d646e09b9d6d7d",
      "text": "Exhibit 23: Performance comp - HC service stocks Last 52 weeks performance",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "52c7749752f20caa",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5a65852cd2f8fafe",
      "text": "Exhibit 24: Performance comp - drug wholesaler stocks Last 52 weeks performance",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "945987fdb798dd91",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e86c72b5d20d4dff",
      "text": "Exhibit 25: Performance comp - generic drug stocks Last 52 weeks performance",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "5da2a40d76acd5d0",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "f87e6d27341c0014",
      "text": "Exhibit 26: Performance comp - pharmacy stocks Last 52 weeks performance",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "494683f7b9d80ec4",
      "text": "Source: Bloomberg, BofA Global Research.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "81a417aabc7e2329",
      "text": "Exhibit 27:Stocks mentioned Prices and ratings for stocks mentioned in this report",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "f1c33201dfedb02b",
      "text": "BofA TickerBloomberg tickerCompany namePriceRatingKYKOF4151 JPKyowa KirinÂ¥ 2.545B-1-7TKPHF4502 JPTakeda Pharm.Â¥ 4.421A-1-7ALPMF4503 JPAstellas PharmaÂ¥ 1.620B-2-7SGIOF4507 JPShionogiÂ¥ 2.550C-1-7CHGCF4519 JPChugai Pharm.Â¥ 6.509B-2-7ESALF4523 JPEisaiÂ¥ 4.538B-3-7OPHLF4528 JPOno Pharm.Â¥ 1.657B-3-7SNPHF4536 JPSanten Pharm.Â¥ 1.563B-1-7SOLTF4565 JPNxera PharmaÂ¥ 925C-1-9DSKYF4568 JPDaiichi SankyoÂ¥ 3.529B-1-7OTSKF4578 JPOtsuka HoldingsÂ¥ 7.766B-1-7TRUMF4543 JPTerumoÂ¥ 2.664B-1-7FUJF4901 JPFujifilm HoldingsÂ¥ 3.511B-2-7PHCCF6523 JPPHC HoldingsÂ¥ 987B-3-8SSMXF6869 JPSysmexÂ¥ 1.868B-1-7SHMZF7701 JPSHIMADZUÂ¥ 3.622B-1-7OCPNF7733 JPOlympus Corp.Â¥ 1.723B-2-7AHICF7747 JPAsahi IntecÂ¥ 2.536B-2-7SMSZF2175 JPSMSÂ¥ 1.583B-3-7MTHRF2413 JPM3Â¥ 2.186C-2-7XEQNF4480 JPMedleyÂ¥ 2.482C-1-9JMDCF4483 JPJMDCÂ¥ 4.162C-1-7SWGHF4887 JPSawai Group HDÂ¥ 1.874C-1-7PHCCF6523 JPPHC HoldingsÂ¥ 987B-3-8MEPDF7459 JPMedipal HoldingsÂ¥ 2.614B-3-7AINPF9627 JPAin HoldingsÂ¥ 6.114B-3-7ALPMYALPMY USAstellas Pharma$ 11.05B-2-7DSNKYDSNKY USDaiichi Sankyo$ 24.50C-1-7FUJYFUJY USFUJIFILM Holdings$ 11.99B-2-7OTSKYOTSKY USOtsuka Holdings$ 26.64B-1-7SGIOYSGIOY USShionogi$ 8.72B-1-7TAKTAK USTakeda Pharm.$ 14.97B-1-7",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "c1928f03bd086d27",
      "text": "Source:BofA Global Research",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "111161ae7c3f59c3",
      "text": "Our 1,500 price objective is based on 20- year DCF modeling with WACC of \\(6.8\\%\\) equity beta of 1.01 (derived from the Bloomberg two- year adjusted equity beta of 0.92, after adjusting for quantitative/qualitative risks), and terminal growth rate of \\(1.0\\%\\) as our main assumptions. The price objective equates to a P/E of 15x our FY3/27 EPS estimate and an EV/EBITDA of 8x. Upside risks: Faster than expected growth of nursing and elderly care staffing demands, withdrawal of competitors from the market, faster adoption of its Kaipoke SaaS platform, new businesses outperform. Downside risks: Intensifying competition or poor macro/economic factors depressing demand for recruiting services, increased competitor activity driving advertising costs higher, potential writedown at its MIMS subsidiary, the performance of new businesses disappoints.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "f58d32fa36ec8e91",
      "text": "Our 2,320 price objective is derived from our DCF model based on 20 years of earnings forecasts for coverage companies, although we also take into consideration other valuation metrics such as P/E and EV/EBITDA. DCF assumptions are a risk- free rate of \\(1.0\\%\\) , an equity premium of \\(6.0\\%\\) , and a perpetual growth rate of \\(1.0\\%\\) . FCF risk is reflected in the equity beta, which considers quantitative risk derived from scenario analysis and qualitative risk based on factors such as management strategies. The equity beta is set at a tiered level within the sector. We base our price objective on a stock beta",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "b5f4391233e674d2",
      "text": "of 0.85, which is two- year adjusted Bloomberg data, and WACC of \\(5.9\\%\\) . Our price objective equates to a P/E of 30x our FY3/27 EPS and an EV/EBITDA of 14x our FY3/27 forecasts. Upside risks to our PO is that revenues generated by new businesses leveraging M3's platform exceeding expectations while downside risks are (1) sustainability of growth coming into question, (2) growth investment expanding substantially above expectations, and (3) risk tolerance for stocks from other sectors increasing.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "400aafc442b0306a",
      "text": "We assign a price objective of \\(\\) 3,200\\(based on our 12 - year DCF model, also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth rate 1.0% and tax rate 40%. Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and it is set at a tiered level within the sector. We use the Bloomberg two - year adjusted beta of 0.59 and base our price objective for the company on a stock beta of 0.65, and WACC of 5.1%. Our PO corresponds to a P/E of 22x our FY12/26 EPS forecast. Downside risks to our PO are a worsening in core product sales trends, cancellation or postponement of new product development or changes in product evaluation, and a worse - than - anticipated negative financial impact from the Orchard Therapeutics acquisition. Upside risks are new profit opportunities not currently factored such as might result from M&A and healthcare policies from different countries that have a positive impact on product sales.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "2e798bb2738dc6ba",
      "text": "Our \\(\\) 4,100\\(price objective is calculated based on the SOTP (sum - of - the - parts) method. A DCF model was used to derive the valuation for the Recruitment PF, which has a high visibility for FCF, and consolidated costs, based on a 20 - year earnings forecast. Our primary DCF assumptions are a risk - free rate of 1.0%, risk premium of 6.0%, WACC of 6.8%, and equity beta of 1.10. The beta is based on an assessment of the degree of risk to future earnings using Bloomberg's two - year adjusted beta. Based on the above, value per share is\\) \\ \\(2,400\\) . EV/sales multiple is the base to assess the Medical PF business, which has a high growth potential, and new businesses. Value per share is \\(\\) 1,730\\(, which is\\) 4x \\(FY12/26 sales forecast. Upside risk to our price objective would be new businesses that leverage the Recruitment PF exceeding expectations. Downside risks are 1) a lack of progress in the government's promotion of healthcare digitalization or failure of Medley to substantially expand its online medication service due to intense competition, 2) pricing erosion in the Recruitment PF that depresses profitability, and 3) insufficient solutions tools for the Medical PF.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "6f20679f8cd7a20f",
      "text": "Our \\(\\) 5,000\\(price objective is derived from our DCF model based on 20 years of earnings forecasts for coverage companies, taking into consideration other valuation metrics such as EV/EBITDA. DCF assumptions are a risk - free rate of 1.0%, an equity premium of 6.0%, and a perpetual growth rate of 1.0%. FCF risk is reflected in the equity beta, which considers quantitative risk derived from scenario analysis and qualitative risk based on factors such as management strategies. The equity beta of 1.04 is based on two - year adjusted Bloomberg data, and WACC of 6.5%. Our price objective corresponds to an EV/EBITDA of 19x FY3/27 forecasts. Downside risks to our price objective are a lack of progress in government policies to advance healthcare digitalization, utilization of healthcare big data falling short of our projections, inability to secure adequate human resources to support its data analysis and processing technology, and equity dilution from issuance of new shares to meet increased investment needs.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "122b29519524046a",
      "text": "We base our JPY5,500 PO (ADR: \\(\\) 19.00)\\(on our 12 - year DCF model and also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%,",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "be002b3ce5c94094",
      "text": "equity risk premium \\(5.5\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use the Bloomberg two- year adjusted beta of 0.67, and base our price objective for the company on a stock beta of 0.74, and WACC of \\(4.0\\%\\) . Our PO equates to a P/E of 11x our FY3/26 Core EPS forecast.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "73f588cbdd0be805",
      "text": "Upside risks are favorable new drug pipeline data and better- than- expected progress in cost reductions. Downside risks are a cancellation or postponement of new product development or changes in product evaluation, inaccuracy in our DCF assumptions and higher- than- expected impairment losses on intangible assets.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "34024e4e2d3eb8b9",
      "text": "We base our JPY1,700 PO (ADR: \\(11.70\\) ) on our 12- year DCF model and also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk- free rate \\(1.5\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use the Bloomberg two- year adjusted beta of 0.68, and base our price objective for the company on a stock beta of 0.75 and WACC of \\(4.5\\%\\) . Our PO equates to a P/E of 16x our FY3/27 EPS forecast. Downside risks to our price objective are lower- than- expected core product sales, cancellation or postponement of new product development or changes in product evaluation, and a divergence between actual conditions and those assumed in our DCF calculations. Upside risks are higher- than- expected growth of Xtandi, accelerated development of new drug candidates and aggressive buybacks.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "1dc4172d48c791a1",
      "text": "We base our JPY3,000 PO (ADR US \\(10.3\\) ) on our 12- year DCF model and also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk- free rate \\(1.0\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1.5\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use the Bloomberg two- year adjusted beta of 0.67, and base our price objective for the company on a stock beta of 0.64, and WACC of \\(5.2\\%\\) . Our PO equates to a P/E of 13x our FY3/27 EPS forecast. Upside risks to our PO are successful development of COVID- 19 therapeutic pill or HIV drug gaining unexpectedly higher share versus competitors. Downside risks are (1) termination of COVID- 19 therapeutic pill development, which would eliminate thematic appeal, (2) a falloff in the flagship HIV franchise, (3) Ping An- Shionogi sales falling substantially below plan, and (4) excessive premiums on external assets to be acquired within the \\(\\) 500bn\\(earmarked for strategic investment.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "42b8c77dd485086f",
      "text": "We base our \\(8,800 PO\\) on our 12- year DCF model and also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk- free rate \\(1.5\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use the Bloomberg two- year adjusted beta of 1.00, and base our price objective for the company on a stock beta of 0.90, and WACC of \\(6.4\\%\\) . Our PO equates to a P/E of 26x our FY12/26 EPS forecast. Downside risks to our price objective are lower core product sales, cancellation or postponement of development of Hemlibra and other new products, intensifying competition overseas for Actemra, a sudden strengthening of domestic government policy to promote the use of biosimilars, and tougher- than- anticipated",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "90d1f1ed45416ebe",
      "text": "competitive environment for hemophilia drug Hemlibra. Upside risks are (1) greater- than- expected oral GLP- 1R agonist orfoglipron sales, (2) major growth in sales of inhouse developed drugs such as Enspryng, (3) early confirmation of the effectiveness of RED SHIFT, and (4) progress developing new drug candidates (especially mid- sized molecule drugs) that can support long- term growth.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "615ec50bf5b0f1f9",
      "text": "We base our \\(\\yen 3,800\\) price objective on our DCF model, while also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk- free rate \\(1.5\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and it is set at a tiered level within the sector. The stock's two- year adjusted beta is 0.89, and we base our price objective on a stock beta of 1.06 and WACC of \\(6.6\\%\\) . Our PO corresponds to a P/E of 20x or FY3/27 EPS forecast. Downside risks are (1) mainstay drugs missing company guidance, (2) cancellation or postponement of new product development or changes in product evaluation, (3) adverse decisions by regulatory authorities in other countries and harsh stances on coverage by public health insurance, and (4) divergence between actual conditions and those assumed in our DCF calculations. Upside risks are greater- than- expected sales of Leqembi and development successes that generate data differentiating new drug candidates.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "1eb517ce0ee706df",
      "text": "We assign a price objective of \\(\\yen 1,400\\) , derived from the DCF method based on 12- year earnings forecasts and taking into account valuations such as P/E and P/B. Our DCF model assumes a risk- free rate of \\(1.5\\%\\) , equity premium of \\(5.5\\%\\) , perpetual growth rate of \\(1.0\\%\\) , and tax rate of \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risks based on new drug development scenario analysis and qualitative risks such as management strategies, and is set at a tiered level within the sector. We use a stock beta of 0.71 and WACC of \\(5.0\\%\\) in our price objective calculation. Our price objective equates to a P/E of \\(11x\\) our estimated FY3/26 EPS. Upside risks to our price objective are stronger- than- expected Optvivo sales growth and stock buybacks. Downside risks are a worse- than- expected NHI price revision, reforms to the US drug pricing system, declining Optvivo sales due to pricing pressure, and discontinued development of new drug candidates.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "c1696485a0fc9d93",
      "text": "We assign a price objective of \\(\\yen 2,100\\) derived from the DCF method based on 10- year earnings forecasts and taking into account valuations such as P/E and P/B. Our DCF model assumes a risk- free rate of \\(1.5\\%\\) , equity premium of \\(5.5\\%\\) , perpetual growth rate of \\(1.0\\%\\) , and tax rate of \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risks based on new drug development scenario analysis and qualitative risks such as management strategies and is set at a tiered level within the sector. Santen's two- year forward stock beta is 0.62, which is what we used to calculate our price objective along with a stock beta of 0.62, WACC of \\(4.6\\%\\) . Our price objective corresponds to a P/E of 19x our FY3/27 forecasts. Downside risks to our price objective are worse- than- anticipated adverse effects on the Japan business from select treatment designations, policy risks for the China business, sluggish new drug sales under the self- funded treatment scheme, and delays or discontinuation of pipeline development. Upside risks are better- than- expected sales of mainstay drugs or new drug candidates and deviations from the assumptions used in our DCF model.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "79e4c3f56560bd78",
      "text": "We base our \\(\\yen 3,400\\) PO on EV/EBITDA of 16.0x on our FY3/27 estimates. We believe this is achievable as Terumo operates in multiple business areas, which leads to stable earnings. Downside risks to our PO are sales growth of highly anticipated WEB falling",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "edec8d98f3cbc324",
      "text": "short of expectations, profit margins being squeezed by growth investment, and product acquisitions and other such activities stalling. Upside risks are higher-than- expected premium valuation in view of high earnings stability, and higher-than- expected growth through M&A.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "b1c6ac26a6acb63f",
      "text": "We base our 1,200 price objective on our 12- year DCF model. Our DCF assumptions are risk- free rate \\(1.5\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use sector beta of 1.0 with taking into accounts of qualitative and quantitative risk, and base our price objective for the company on a stock beta of 2.0, and WACC of \\(8.8\\%\\) . Our PO equates to a P/E of 26x our FY12/29 EPS forecast. Downside risks are shortfall in overall earnings or sales of in- house products relative to market expectations, and discontinuation of development for new drug candidates. Upside risk is the emergence of new drug candidates developed by the company that lead to earnings growth.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "ec8c6db7cca5e354",
      "text": "We base our JPY5,600 PO (ADR: \\(38.60\\) ) on our 12- year DCF model and also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk- free rate \\(1.5\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use the Bloomberg two- year adjusted beta of 0.87, and base our price objective for the company on a stock beta of 0.78, and WACC of \\(5.7\\%\\) . Our PO equates to a P/E of 32x our FY3/27 EPS forecast. Downside risks to our PO are the sudden emergence of adverse side effects, intensifying competition, declining profits as a result of increased pressure from healthcare policies, delays in or discontinuation of new drug development, development setbacks in clinical trials, and greater- than- expected costs (mainly SG&A expenses in the US), and changes to product assessment. Upside risks are greater- than- expected profits on easing of competition or new drug demand, new profit opportunities not currently discounted such as might result from M&A, and healthcare policies from different countries that have a positive impact on product sales. Upside risk related to pipeline is that P3 trials show a positive outcome.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "60c1cfaca871ab74",
      "text": "We base our 10,400 (ADR: \\(35.90\\) ) price objective on SOTP analysis for the pharmaceutical segment, biopharma business, and the NC/consumer product business. For the biopharma business, we use a 12- year DCF model, and our DCF assumptions are risk- free rate \\(1.5\\%\\) , equity risk premium \\(5.5\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which takes into account quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies, and is set at a tiered level within the sector. We use the Bloomberg two- year adjusted beta of 0.89, so base our price objective for the company on a stock beta of 0.97, and WACC of \\(6.6\\%\\) . Our price objective corresponds to a P/E of 21x our FY12/26 EPS forecast. Upside risks to our price objective are greater- than- expected sales of in- house drugs, increases in royalty income, and evidence that differentiates Otsuka drug candidates. Downside risks are weaker- than- anticipated sales of mainstay drugs, cancellation or postponement of new product development or changes in product evaluation, commercialization of novel competing drugs, and divergence between actual conditions and those assumed in our DCF calculations.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "4350080a9fdfe366",
      "text": "Sawai Group Holdings (4887 / SWGHF)",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "e4868e991067c74c",
      "text": "We calculate our JPY2,200 price objective using a 20- year DCF model, and taking into account valuations such as P/E and P/B. Our DCF assumptions are risk- free rate \\(1.0\\%\\) equity risk premium \\(6.0\\%\\) , terminal growth \\(1.0\\%\\) and tax rate \\(40\\%\\) . Individual company FCF risk is reflected in the stock beta, which factors in quantitative risk based on new drug development scenario analysis and qualitative risk based on factors such as management strategies. We use an adjusted 2- year beta of 0.76 based on the data provided by Bloomberg, and WACC of \\(4.1\\%\\) . Our PO equates to a P/E of \\(12x\\) our FY3/27 EPS forecast. Downside risks to our price objective are delayed expansion of the generic drug market, intensifying competition, pressure on profits due to changes to the NHI price system, a worsening in the balance sheet stemming from expanded capital investment, and changes to government stimulatory policies. Upside risks are better- than- projected market penetration of generic drugs, an easing of competition in the generic drug market, and positive progress in government debates on the NHI price system and generic stimulus measures.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "2ca3662dfcc30611",
      "text": "We calculate our price objective of \\(3,910\\) (ADR \\(13.5\\) ) based on SOTP on our FY3/27 estimates, as Fujifilm operating multiple businesses with differing growth cycles and risks. We also cross- checked our PO using DCF and EV/EBITDA. Upside risk for our PO are (1) greater- than- expected unit price growth and margin improvement in the bio CDMO business, (2) positive market view of additional investment in the bio CDMO business, and (3) market share growth and margin improvement in the medical systems business. Downside risks are sluggish promotion and marketing outcome for overseas healthcare businesses, and slower than expected cash generation timing for bio CDMO business.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "55ea731437c75850",
      "text": "We base our \\(1,010\\) price objective on P/B of \\(0.90x\\) in FY3/25. We value MedTech stocks using EV/EBITDA multiples, but as PHC is under restructuring and earnings visibility is low, we use PBR as a multiple for PHC. PO has been cross- checked using SOTP and DCF model. Upside risk to our PO is investor confidence improving on financial structure improvement and growth strategy. Downside risks are diabetes management (DM) segment share does not increase as much, cost- cutting does not take effect, relatively sizable intangible assets receive lower valuation than expected, becomes worse and negatively affects earnings for FY3/25 and beyond.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "306928e257554e79",
      "text": "Our \\(2,600\\) PO is based on our FY3/27 estimates and a two- year forward EV/EBITDA of \\(11.9x\\) , which is the two- year average. Upside risks to our PO are greater- than- expected sales growth stemming from success of the solutions- centered marketing in developed countries, larger- than- expected contribution from haemostasis business in Europe and the US, and increased contributions from new businesses. Downside risks are JPY appreciation, weak performance of new businesses, and sales erosion in China owing to \"buy Chinese\" policy.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "be5a9edebc48e472",
      "text": "We base our price objective of JPY2,500 on DCF using 20 years of earnings forecasts for coverage companies. We set our fair value at the theoretical share price derived from DCF. The DCF assumptions are a risk- free rate of \\(1.0\\%\\) , equity premium of \\(6.0\\%\\) , perpetual growth rate of \\(1\\%\\) , and tax rate of \\(40\\%\\) . For equity beta, we used adjusted Bloomberg data for the past two years and adjust based on qualitative/quantitative business volatility. In Medipal's case, the equity beta used for calculation is 0.91 and WACC is \\(6.5\\%\\) . Our price objective corresponds to P/B of \\(0.77x\\) based on our FY3/26 BPS estimate. The factors that may result in the share price diverging significantly from our price objective are (1) earnings exceeding/missing company guidance, (2) additional M&A activity, and (3) diversified business profits exceeding/lowering expectations. Downside risks to our price objective are margin deterioration from harsh pricing",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "f7b816b283f87450",
      "text": "negotiations with medical institutions or suppliers that trigger excessive pricing competition within the industry, higher invoice prices for high- margin generic drugs, reduced sales of COVID- 19- related products, and possible sluggish return on investment. Upside risks are greater- than- expected growth in the pharmaceutical market and the emergence of new profit opportunities, for example as the result of M&A.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "e4fd94c04fbc313a",
      "text": "Price objective is 4,300, which we base on an EV/EBITDA of 11.2x and our FY3/27 forecasts. 11.2x is the three- year average (excluding the term after March 2025 when tariff fears led to valuation discount) of two- year forward EV/EBITDA. Upside risks are (1) earlier- than- expected recovery in demand for China business, and (2) greater- than- expected contribution from new client base/new business in North America and in the healthcare field.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "1cc5cf3a9c33823d",
      "text": "Downside risks are (1) decrease in analytical equipment demand because of economic fluctuations, (2) greater- than- expected increase in R&D costs, (3) increase in investments including human capital and marketing costs, and (4) geopolitical risks from high exposure to China.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "92c909240e93828c",
      "text": "We base our 1,820 PO on a two- year forward EV/EBITDA of 9.0x. Given concerns on issues identified by the US Food and Drug Administration (FDA) are rising again, we think \\(10\\%\\) discount is appropriate. Upside risks to our PO are stronger sales on newly launched EVIS X1 and cost reduction. Downside risks are the new GI endoscope model failing to impress and an excessively overpriced M&A for therapeutic devices.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "60bda5218bb2ae73",
      "text": "We base our 2,800 PO on a two- year forward EV/EBITDA of 15.5x. Five- year range is 13- 42x, but we think 15.5x is justified given the change in pipelines and comparison with peers. Upside risk factors are expansion of US market share, accelerated growth of the Chinese business, and greater contributions from new product launches. Downside risk factors are lower- than- expected PCI procedure numbers, margins being squeezed by growth investment, a stronger- than- expected yen, and a risk of a possible souring of investment sentiment on geopolitical risks in China.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "ce521a6ec4fe06ae",
      "text": "We base our 5,100 PO on Sum- of- the- parts of dispensing pharmacy and retail segments, using a two- year forward EV/EBITDA multiples. We applied 5.0x (pricing in synergy from the acquisition) for dispensing pharmacy segment, and 7.2x for retail segment on FY4/27 earnings, referring to peer stocks average. Upside risks to our price objective are 1) accelerated opening of large numbers of onsite pharmacies, 2) attractively priced M&A transactions, 3) larger than expected cost reduction. Downside risks are 1) delayed recovery from price revisions, 2) difficulties in negotiating prices with wholesalers, 3) excessive M&A prices, 4) delays in the opening of on- site pharmacies, 5) unexpected cost increases, 6) low reliability of earnings guidance, and 7) government policy could adversely affect pharmacy business.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "eccc3170631d37ce",
      "text": "Special DisclosuresBoFA Securities is currently acting as financial advisor to Otsuka Medical Devices Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd., in connection with the proposed partial stake sale in MicroPort Scientific Corporation, an equity- method affiliate of Otsuka Holdings Co., Ltd., which was announced on July 25, 2025.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "2118fe9150fab626",
      "text": "APR-Healthcare Coverage Cluster",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "b7346e773c6a57d1",
      "text": "Investment ratingCompanyBofA TickerBloomberg symbolAnalystBUYAdicon HoldingsADCNF9860 HKDavid LiAier Eye HospitalXAEOF300015 CHDavid LiAngelalign Technology IncAGLFF6699 HKDavid LiApollo HospitalXWQAFAPHS INNeha ManpuriaAurobindoXLZFFARBP INNeha ManpuriaAustralian Clinical LabsXAUKFACL AULyanne HarrisonBaiyunshanGZPHF874 HKSandra SunBangkok Chain HospitalBKKFFBCH TBTeerapol Udomevj, CFABeijing Tongrentang Co., LimitedBJTGF600085 CHDavid LiBeOne Medicines LtdBEIGF6160 HKDavid LiBeOne Medicines LtdONCONC USDavid LiBioconXLOFFBIOS INNeha ManpuriaBumrungrad HospitalBUHHFBH TBTeerapol Udomevj, CFACansino BioCASBF6185 HKDavid LiChularat Hospital GroupXCOOFCHG TBTeerapol Udomevj, CFACR PharmaceuticalCRPGF3320 HKDavid LiCSL LimitedCMXHFCSL AULyanne HarrisonCSL LimitedCSLYCSLY USLyanne HarrisonDaiichi SankyoDSKYF4568 JPKoichi MameganoDaiichi SankyoDSNKYDSNKY USKoichi MameganoDivis LaboratoriesXXQPFDIV INNeha ManpuriaDr. Reddy&#x27;sXDLZFDRRD INNeha ManpuriaDr. Reddy&#x26;sRDYRDY USNeha ManpuriaFortis HealthXFFTFFORH INNeha ManpuriaGiant BiogeneGBHCF2367 HKEthan CuiGland PharmaXGLPFGLAND INNeha ManpuriaGushengfangGSHTF2273 HKDavid LiHansohHNSPF3692 HKDavid LiHuadong MedicineXCPDF000963 CHEthan CuiHualan BiologicalXCBEF002007 CHEthan CuiHygeia HealthcareHYHHF6078 HKEthan CuiIHH Healthcare BerhadIHHHFIHH MKNeha ManpuriaIHH Healthcare BhdXFAHFIHH SPNeha ManpuriaImeikZMITF300896 CHEthan CuiInnoventIVBXF1801 HKDavid LiIntegral DiagnosticsITGDFIDX AULyanne HarrisonJinxin FertilityJXFG1951 HKEthan CuiJinyu Bio-TechXMTDF600201 CHDavid LiJMDCJMDCF4483 JPRitsuo WatanabeKyowa KirinKYKOF4151 JPKoichi MameganoMedleyXEQNF4480 JPRitsuo WatanabeMindrayXDVVF300760 CHSandra SunNxera PharmaSOLTF4565 JPKoichi MameganoOtsuka HDOTSKF4578 JPKoichi MameganoOtsuka HDOTSKYOTSKY USKoichi MameganoPharmaronPHBBF3759 HKDavid LiPolynovoCALZFPNV AULyanne HarrisonPram 9 HospitalXPNHFPR9 TBTeerapol Udomevj, CFAResMed IncRSMDFRMD AULyanne HarrisonResMed Inc.RMDRMD USLyanne HarrisonSanten Pharm.SNPHF4536 JPKoichi MameganoSawai Group HoldingsSWGHF4887 JPRitsuo WatanabeShanghai PharmaceuticalsSHPMF2607 HKDavid LiShanghai United ImagingXCAOF688271 CHSandra SunSHIMADZUSHMZF7701 JPRitsuo WatanabeShionogiSGIOF4507 JPKoichi MameganoShionogiSGIOYSGIOY USKoichi MameganoSino BiopharmSBMFF1177 HKDavid LiSinopharmSHTDF1099 HKDavid LiSonic Healthcare LimitedSKHCFSHL AULyanne HarrisonSysmexSSMXF6869 JPRitsuo WatanabeTakeda Pharm.TKPHF4502 JPKoichi MameganoTakeda Pharm.TAKTAK USKoichi MameganoTerumoTRUMF4543 JPRitsuo Watanabe",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "7c1c98344a680434",
      "text": "APR-Healthcare Coverage Cluster",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "c1fab6c66f6dfe67",
      "text": "Investment ratingCompanyBofA TickerBloomberg symbolAnalystTigerMedHTMDF3347 HKDavid LiWuxi ApptecWUXIF2359 HKDavid LiWuxi ApptecXLUHF603259 CHSandra SunYunnan BaiyaoYBAIF000538 CHDavid LiZhifeiXCHOF300122 CHDavid LiNEUTRALAlkemXAMLFALKEM INNeha ManpuriaAsahi IntecAHICF7747 JPRitsuo WatanabeAstellas PharmaALPMF4503 JPKoichi MameganoAstellas PharmaALPMYALPMY USKoichi MameganoBangkok Dusit Medical ServicesBDMSFBDMS TBTeerapol Udomev, CFAChugai Pharm.CHGCF4519 JPKoichi MameganoCochlear LimitedCHEOFCOH AULynne HarrisonEBOS Group LimitedEBOSFEBO NZLynne HarrisonEBOS Group LimitedXEBOFEBO AULynne HarrisonEverest MedicineXMLKF1952 HKDavid LiFisher &amp;amp; Paykel HealthcareXPAXFFPH AULynne HarrisonFisher &amp;amp; Paykel HealthcareFSPKFFPH NZLynne HarrisonFujifilm HoldingsFUJIF4901 JPRitsuo WatanabeFUJIFILM HoldingsFUJIFFUJIF USRitsuo WatanabeKelun-BiotechXSKBF6990 HKDavid LiLupinXEFSFLPC INNeha ManpuriaM3MTHRF2413 JPRitsuo WatanabeMax HealthcareXMHIFMAXHEALT INNeha ManpuriaNew Industries Biomedical EngineeringXSNQF300832 CHSandra SunOlympus Corp.OCPNF7733 JPRitsuo WatanabeRamsay Health Care LimitedRMSYFRHC AULynne HarrisonTopchoice MedicalXZDXF600763 CHEthan CuiTorrent PharmaTOPHFTRP INNeha ManpuriaWuXi BiologicsWXIBF2269 HKDavid LiZai LabZLABZLAB USDavid LiZai LabXCDZF9688 HKDavid LiZydus LifesciencesXMQLFZYDUSLIF INNeha ManpuriaUNDERPERFORMAin HoldingsAINPF9627 JPRitsuo WatanabeAsymchem LaboratoriesXALPF002821 CHDavid LiAutobio Diagnostics Co LtdXQDXF603658 CHSandra SunBaiyunshanXOUFF600332 CHSandra SunBeijing Wantai Biological PharmacyXBHIIF603392 CHDavid LiCiplaXCLAFCIPLA INNeha ManpuriaCSPC PharmaceuticalCHJTF1093 HKEthan CuiEisaiESALF4523 JPKoichi MameganoFrontageFGHQF1521 HKDavid LiHelalus LimitedPHCRFHLS AULynne HarrisonHengrui MedicineXMOKF600276 CHDavid LiJoinn LabXQTSF6127 HKDavid LiJoinn LabJOLCF603127 CHDavid LiMankind PharmaXDXZFMANKIND INNeha ManpuriaMedipal HoldingsMEPDF7459 JPRitsuo WatanabeOno Pharm.OPHLF4528 JPKoichi MameganoOvtekXOCKF300595 CHDavid LiPharmaronXLYGF300759 CHDavid LiPHC HoldingsPHCCF6523 JPRitsuo WatanabePien Tze HuangXUVHF600436 CHSandra SunShanghai PharmaceuticalsXKCRF601607 CHDavid LiSMSSMSZF2175 JPRitsuo WatanabeSun PharmaXPUCFSUNP INNeha ManpuriaTigerMedXHTHF300347 CHDavid LiYifeng PharmacyXYHCF603939 CHEthan CuiRSTRMicroPortMCRPF853 HKSandra SunTRYTXHXTF9164 JPRitsuo Watanabe",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "3fabd119c5b1df73",
      "text": "e expenses from the issuer for such visits.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "2efacd9c0f3b0f12",
      "text": "p p p p p p p p p p p p p p p p p p p p p",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "2f42c8611f18d2d6",
      "text": "The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "a6da20d5c99b3338",
      "text": "e with any investment decision, or for a necessary explanation of its contents.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "a2c05307d379b653",
      "text": "Offers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "636885ff0ec97e0e",
      "text": "Refer to BofAS Global Research policies relating to conflicts of interest.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "884d17159a35aff5",
      "text": "BofAS Securities includes BofAS Securities, Inc. (BofAS) and its affiliates. Investors should contact their BofAS Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. BofAS Securities is a global brand for BofAS Global Research.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "9294bb153ee3f4b7",
      "text": "Information relating to Non- US affiliates of BofAS Securities and Distribution of Affiliate Research Reports:",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "e042857a7d6d6bd6",
      "text": "BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated (\"MLPF&S\") may in the future distribute, information of the following non- US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by the Financial Sector Conduct Authority; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofAS Securities Europe SA is authorized by the AutoritÃ© de ContrÃ´le Prudentiel et de RÃ©solution (ACPR) and regulated by the ACPR and the AutoritÃ© des MarchÃ©s Financiers (AMF). BofAS Securities Europe SA (\"BofASE\") with registered address at 51, rue La BoÃ©tie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code MonÃ©taire et Financier (Monetary and Financial Code), BofASE is an establishment de crÃ©dit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the AutoritÃ© de ContrÃ´le Prudentiel et de RÃ©solution (ACPR) and regulated by the ACPR and the AutoritÃ© des MarchÃ©s Financiers. BofASE's share capital can be found at www.bofam.com/BofASdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en EspaÃ±a, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the ComisiÃ³n Nacional Bancaria y de Valores; BofAS Japan: BofAS Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofAS Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de TÃ­tulos e Valores MobiliÃ¡rios, regulated by ComissÃ£o de Valores MobiliÃ¡rios; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority. This information has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA. Details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to Wholesale clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BofA Europe (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofAS Securities entities, including BofA Europe and BofASE (France), may outsource/delete the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofAS Securities group. You may be contacted by a different BofAS Securities entity acting for and on behalf of your service provider where permitted by applicable law. This does not change your service provider. Please refer to the Electronic Communications Disclaimers for further information.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "07dea77301f39f6f",
      "text": "This information has been prepared and issued by BofAS and/or one or more of its non- US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non- US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "2a3f2e69bd8632a5",
      "text": "Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofAS Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofAS Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "148a22a05ee5cdd4",
      "text": "Securities and other financial instruments referred to herein, or recommended, offered or sold by BofAS Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, NA). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "89c78858d5cacec5",
      "text": "This report may contain a short- term trading idea or recommendation, which highlights a specific near- term catalyst or event impacting the issuer or the market that is anticipated to have a",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "56b22774111d28c3",
      "text": "reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short- term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "26c867932763363a",
      "text": "BofA Securitie is aate that the implemenation of the ideas expressed in this report may depend upon an investor's ability to short securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting shortselling in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "eb6be7054c88dd42",
      "text": "Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "4f407af595db10f7",
      "text": "BofA or one of its affliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofA or one of its affliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "484284b456c27766",
      "text": "BofA Securitie, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofA for the provision of research services for a separate fee, and in connection therewith BofA may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofA has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofA). If such recipient uses the services of BofA in connection with the sale or purchase of a security referred to herein, BofA may act as principal for its own account or as agent for another person. BofA is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "55cd97ef2b976635",
      "text": "Copyright 2025 Bank of America Corporation. All rights reserved. iQdatabae is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. This document and its content is provided solely for informational purposes and cannot be used for training or developing artificial intelligence (AI) models or as an input in any AI application (collectively, an AI tool). Any attempt to utilize this document or any of its content in connection with an AI tool without explicit written permission from BofA Global Research is strictly prohibited. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly- available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "157aa0444c3d2bd5",
      "text": "Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co- plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "b91fa2ff70ff470c",
      "text": "This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of securities. None of BofA any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "9ae66eefa0437dd8",
      "text": "Any information relating to sustainability in this material is limited as discussed herein and is not intended to provide a comprehensive view on any sustainability claim with respect to any issuer or security.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "ead3c77e6d225f1a",
      "text": "Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "eabead4d4279ec9a",
      "text": "The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third- party websites. BofA Securities is not responsible for the content of any third- party website or any linked content contained in a third- party website. Content contained on such third- party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third- party website is at your own risk, and you should always review the terms and privacy policies at third- party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "454dfbc8f077bcc7",
      "text": "All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "5e9774615ec14121",
      "text": "Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy- related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "b84a1553be6e4fe3",
      "text": "Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "8daeff5ca509b034",
      "text": "In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofA's or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies. Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.",
      "page": 26,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "e1e651d2efa1d5cc",
      "name": "AFS License",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "85f68b724587f17d",
      "name": "Abbott Laboratories",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "85209ee882f03013",
      "name": "Abilify Maintena",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "610edadada2d2f24",
      "name": "Adicon Holdings",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "27e7d001805fe0c8",
      "name": "Advisory Committee",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e195d3a47b7917a1",
      "name": "Affiliate Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8ffc189db47b47e1",
      "name": "Aier Eye",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4106ad8b8c1026f9",
      "name": "Ain HD",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "645f128997f142a3",
      "name": "Ain Holdings",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7e8b5acc866b7bb1",
      "name": "Allergy Asthma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0932cb8d2b0b0ac7",
      "name": "America Corporation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b0c2f9a72e612607",
      "name": "America Europe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "867a9dfe274a629d",
      "name": "American Academy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "38efa2e9cded7911",
      "name": "American College",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "756f35f2e04b7108",
      "name": "American Heart",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f497b5c8d3d398b0",
      "name": "American Menopause",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cbf19603e95d6dfd",
      "name": "American Society",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "21ada4146889c3ba",
      "name": "Among Healthcare",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "272935ad9dbf62f4",
      "name": "Among Medtech",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "517917b86efb07cf",
      "name": "Analyst Certification",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "line",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -5,
              "max": 25
            }
          }
        },
        "series": [
          {
            "name": "Ain",
            "unit": "%",
            "values": [
              8.5,
              12,
              9,
              10.5,
              10.5,
              14.5,
              10,
              10,
              7,
              10,
              9,
              4,
              4,
              11.5,
              9,
              9.5,
              9.5,
              2,
              8,
              10.5,
              10.5,
              16,
              12.5
            ]
          },
          {
            "name": "Qol",
            "unit": "%",
            "values": [
              8.5,
              9,
              6,
              5,
              6.5,
              8,
              -2,
              5.5,
              6,
              2,
              9.5,
              1.5,
              1.5,
              5,
              6,
              5.5,
              5.5,
              -3,
              4,
              5,
              3,
              2,
              1
            ]
          },
          {
            "name": "MSNW",
            "unit": "%",
            "values": [
              5.5,
              7.5,
              3,
              4.5,
              7,
              9.5,
              1,
              10,
              4,
              1,
              11.5,
              4,
              7.5,
              8,
              4.5,
              6.5,
              6.5,
              2.5,
              6,
              5.5,
              4,
              5.5,
              4.5
            ]
          },
          {
            "name": "Sugi",
            "unit": "%",
            "values": [
              13.5,
              14.5,
              13,
              13.5,
              14,
              18.5,
              12,
              14,
              14,
              13.5,
              10,
              13.5,
              9,
              12,
              14,
              13,
              12,
              8,
              10.5,
              10.5,
              7,
              7.5,
              7.5
            ]
          },
          {
            "name": "Matsu-Coco",
            "unit": "%",
            "values": [
              7.5,
              6,
              1.5,
              3,
              5.5,
              6.5,
              -1,
              5,
              5.5,
              -1,
              5,
              1,
              -3,
              4,
              3.5,
              4,
              4,
              -1,
              4.5,
              4,
              3.5,
              4,
              3.5
            ]
          }
        ],
        "figure_id": "cee3fffd8d4280d6",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-23",
              "Oct-23",
              "Dec-23",
              "Feb-24",
              "Apr-24",
              "Jun-24",
              "Aug-24",
              "Oct-24",
              "Dec-24",
              "Feb-25",
              "Apr-25",
              "Jun-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 40,
              "max": 160
            }
          }
        },
        "series": [
          {
            "name": "Performance vs TOPIX",
            "unit": "%",
            "values": [
              -1.5,
              -5.0,
              -1.0,
              -10.0,
              -15.0,
              -10.0,
              -5.0,
              -10.0,
              -15.0,
              -18.0,
              -15.0,
              -25.0
            ]
          },
          {
            "name": "TPX",
            "unit": "%",
            "values": [
              100.0,
              98.0,
              100.0,
              105.0,
              110.0,
              120.0,
              110.0,
              115.0,
              110.0,
              115.0,
              105.0,
              125.0
            ]
          },
          {
            "name": "TPPHRM",
            "unit": "%",
            "values": [
              100.0,
              95.0,
              100.0,
              105.0,
              100.0,
              110.0,
              115.0,
              105.0,
              100.0,
              100.0,
              95.0,
              100.0
            ]
          }
        ],
        "figure_id": "a9fb7bc72b6111d2",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -30,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "Internal medicine",
            "unit": "%",
            "values": [
              2,
              3,
              0,
              -2,
              -3,
              -1,
              6,
              0,
              -1,
              -10,
              -15,
              -20,
              -22,
              -15,
              -15,
              -12,
              -10,
              -15,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Pediatric",
            "unit": "%",
            "values": [
              7,
              8,
              -2,
              -10,
              -12,
              -5,
              -1,
              -5,
              -10,
              -28,
              -1,
              -5,
              -8,
              -5,
              -3,
              -2,
              -3,
              -25,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Gynecology",
            "unit": "%",
            "values": [
              1,
              2,
              1,
              1,
              2,
              1,
              0,
              5,
              6,
              0,
              -5,
              -2,
              -5,
              -3,
              -2,
              2,
              1,
              0,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "ENT",
            "unit": "%",
            "values": [
              13,
              12,
              4,
              2,
              5,
              8,
              -8,
              6,
              -2,
              -5,
              -8,
              -5,
              -2,
              5,
              6,
              4,
              2,
              -8,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "39453afa79af28a4",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -10,
              "max": 5
            }
          }
        },
        "series": [
          {
            "name": "In-patient YoY",
            "unit": "%",
            "values": [
              1.5,
              0.5,
              0.8,
              1.5,
              1.0,
              1.8,
              1.5,
              1.0,
              0.5,
              0.2,
              0.8,
              0.0,
              -0.5,
              -0.2,
              0.0,
              0.5,
              1.5,
              1.0,
              0.8,
              0.5,
              0.0,
              null,
              null
            ]
          },
          {
            "name": "Out-patient YoY",
            "unit": "%",
            "values": [
              -2.5,
              2.0,
              -2.0,
              -3.0,
              -1.0,
              -0.5,
              -6.0,
              2.0,
              -1.0,
              -8.0,
              4.0,
              -5.0,
              -4.0,
              1.0,
              -3.0,
              -1.0,
              1.5,
              -2.0,
              -1.0,
              -1.0,
              -4.0,
              null,
              null
            ]
          }
        ],
        "figure_id": "ba8b1a74a61e6581",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 12,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25",
              "Aug-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.4,
              "max": 1.4
            }
          }
        },
        "series": [
          {
            "name": "Shionogi",
            "unit": null,
            "values": [
              1.0,
              0.98,
              0.95,
              0.93,
              0.95,
              0.98,
              1.0,
              1.02,
              1.05,
              1.1,
              1.15,
              1.18,
              1.2
            ]
          },
          {
            "name": "Takeda",
            "unit": null,
            "values": [
              1.0,
              0.98,
              0.95,
              0.93,
              0.9,
              0.92,
              0.95,
              0.98,
              1.0,
              1.02,
              1.05,
              1.08,
              1.1
            ]
          },
          {
            "name": "Astellas",
            "unit": null,
            "values": [
              1.0,
              0.98,
              0.95,
              0.93,
              0.9,
              0.88,
              0.85,
              0.82,
              0.8,
              0.82,
              0.85,
              0.88,
              0.9
            ]
          },
          {
            "name": "Otsuka",
            "unit": null,
            "values": [
              1.0,
              0.98,
              0.95,
              0.93,
              0.9,
              0.88,
              0.85,
              0.82,
              0.8,
              0.78,
              0.75,
              0.72,
              0.7
            ]
          },
          {
            "name": "Chugai",
            "unit": null,
            "values": [
              1.0,
              0.95,
              0.9,
              0.88,
              0.85,
              0.82,
              0.8,
              0.78,
              0.75,
              0.72,
              0.7,
              0.68,
              0.65
            ]
          },
          {
            "name": "Santen",
            "unit": null,
            "values": [
              1.0,
              0.95,
              0.9,
              0.85,
              0.8,
              0.78,
              0.75,
              0.72,
              0.7,
              0.68,
              0.65,
              0.62,
              0.6
            ]
          },
          {
            "name": "K_Kirin",
            "unit": null,
            "values": [
              1.0,
              0.95,
              0.9,
              0.85,
              0.8,
              0.75,
              0.7,
              0.68,
              0.65,
              0.62,
              0.6,
              0.58,
              0.55
            ]
          },
          {
            "name": "Eisai",
            "unit": null,
            "values": [
              1.0,
              0.9,
              0.85,
              0.8,
              0.75,
              0.7,
              0.65,
              0.6,
              0.58,
              0.55,
              0.52,
              0.5,
              0.48
            ]
          },
          {
            "name": "Ono",
            "unit": null,
            "values": [
              1.0,
              0.9,
              0.8,
              0.75,
              0.7,
              0.65,
              0.6,
              0.55,
              0.5,
              0.48,
              0.45,
              0.42,
              0.4
            ]
          },
          {
            "name": "D_Sankyo",
            "unit": null,
            "values": [
              1.0,
              0.9,
              0.8,
              0.7,
              0.65,
              0.6,
              0.55,
              0.5,
              0.45,
              0.42,
              0.4,
              0.38,
              0.35
            ]
          },
          {
            "name": "Nxera",
            "unit": null,
            "values": [
              1.0,
              0.8,
              0.7,
              0.6,
              0.55,
              0.5,
              0.45,
              0.4,
              0.35,
              0.32,
              0.3,
              0.28,
              0.25
            ]
          }
        ],
        "figure_id": "03602d8ce6e8b6f0",
        "provenance": {
          "page": 12
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 12,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.4,
              "max": 1.2
            }
          }
        },
        "series": [
          {
            "name": "A_Intecc",
            "unit": null,
            "values": [
              1.0,
              1.05,
              1.0,
              1.08,
              1.1,
              1.05,
              0.98,
              0.98,
              1.0,
              1.0,
              1.0,
              1.05
            ]
          },
          {
            "name": "Terumo",
            "unit": null,
            "values": [
              0.98,
              1.0,
              0.95,
              1.0,
              1.0,
              1.0,
              0.95,
              0.9,
              0.85,
              0.9,
              0.95,
              0.98
            ]
          },
          {
            "name": "Fujifilm",
            "unit": null,
            "values": [
              1.0,
              1.02,
              1.0,
              0.95,
              0.9,
              0.85,
              0.8,
              0.8,
              0.85,
              0.88,
              0.9,
              0.95
            ]
          },
          {
            "name": "PHC",
            "unit": null,
            "values": [
              1.0,
              0.98,
              0.9,
              0.85,
              0.8,
              0.75,
              0.7,
              0.68,
              0.7,
              0.75,
              0.8,
              0.85
            ]
          },
          {
            "name": "Sysmex",
            "unit": null,
            "values": [
              1.0,
              0.95,
              1.0,
              0.9,
              0.85,
              0.8,
              0.75,
              0.7,
              0.75,
              0.78,
              0.8,
              0.85
            ]
          },
          {
            "name": "Shimadizu",
            "unit": null,
            "values": [
              1.0,
              0.98,
              0.95,
              0.9,
              0.85,
              0.8,
              0.75,
              0.7,
              0.68,
              0.7,
              0.75,
              0.8
            ]
          },
          {
            "name": "Olympus",
            "unit": null,
            "values": [
              1.0,
              0.95,
              0.9,
              0.85,
              0.8,
              0.75,
              0.7,
              0.65,
              0.6,
              0.65,
              0.7,
              0.65
            ]
          }
        ],
        "figure_id": "8af290896bf182aa",
        "provenance": {
          "page": 12
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -20,
              "max": 30
            }
          }
        },
        "series": [
          {
            "name": "Medical",
            "unit": "%",
            "values": [
              18,
              23,
              19,
              20,
              20.5,
              21,
              16,
              23,
              21,
              15,
              22,
              19,
              20.5,
              18.5,
              18.5,
              18,
              17,
              14
            ]
          },
          {
            "name": "Dispensing pharmacies",
            "unit": "%",
            "values": [
              6,
              6.5,
              3,
              4,
              5,
              8.5,
              -4,
              6,
              3,
              -2,
              6,
              -3,
              -4,
              3,
              4,
              5,
              -1,
              -5
            ]
          },
          {
            "name": "Home medical nursing",
            "unit": "%",
            "values": [
              4,
              2,
              1,
              3,
              4,
              0,
              -2,
              2,
              1,
              2,
              1,
              2,
              2,
              3,
              3.5,
              4,
              3,
              2
            ]
          }
        ],
        "figure_id": "070c3991a65c03d9",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 13,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.8,
              "max": 1.2
            }
          }
        },
        "series": [
          {
            "name": "Toho",
            "unit": null,
            "values": [
              1.01,
              1.05,
              0.98,
              0.93,
              0.9,
              0.9,
              0.95,
              1.02,
              1.05,
              1.08,
              1.15,
              1.18
            ]
          },
          {
            "name": "Suzuken",
            "unit": null,
            "values": [
              1.0,
              0.98,
              1.02,
              0.95,
              0.92,
              0.9,
              0.98,
              1.0,
              1.05,
              1.02,
              1.08,
              1.1
            ]
          },
          {
            "name": "Medipal",
            "unit": null,
            "values": [
              0.99,
              0.95,
              0.98,
              0.9,
              0.88,
              0.85,
              0.88,
              0.92,
              0.95,
              0.98,
              1.0,
              1.05
            ]
          },
          {
            "name": "Alfresa",
            "unit": null,
            "values": [
              1.02,
              0.92,
              0.95,
              0.9,
              0.88,
              0.82,
              0.85,
              0.88,
              0.82,
              0.8,
              0.85,
              0.9
            ]
          }
        ],
        "figure_id": "8588bd96c25d012f",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 13,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.0,
              "max": 1.8
            }
          }
        },
        "series": [
          {
            "name": "M3",
            "unit": null,
            "values": [
              1.0,
              1.0,
              1.2,
              1.0,
              0.95,
              1.0,
              1.4,
              1.2,
              1.1,
              1.5,
              1.4,
              1.6
            ]
          },
          {
            "name": "Medpeer",
            "unit": null,
            "values": [
              1.0,
              1.05,
              1.0,
              0.8,
              0.78,
              0.75,
              0.55,
              0.55,
              0.65,
              0.7,
              0.7,
              0.72
            ]
          },
          {
            "name": "JMDC",
            "unit": null,
            "values": [
              1.0,
              1.1,
              1.15,
              1.0,
              0.95,
              1.0,
              0.8,
              0.7,
              0.8,
              0.9,
              1.05,
              1.08
            ]
          },
          {
            "name": "Medley",
            "unit": null,
            "values": [
              1.0,
              1.0,
              1.1,
              1.28,
              1.1,
              1.18,
              1.08,
              0.9,
              0.95,
              1.05,
              0.9,
              0.8
            ]
          },
          {
            "name": "SMS",
            "unit": null,
            "values": [
              1.0,
              0.95,
              0.9,
              0.78,
              0.75,
              0.7,
              0.55,
              0.5,
              0.5,
              0.6,
              0.65,
              0.7
            ]
          }
        ],
        "figure_id": "10a2c173185f0e29",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 14,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.4,
              "max": 3.4
            }
          }
        },
        "series": [
          {
            "name": "Nchozai",
            "unit": null,
            "values": [
              1.0,
              1.1,
              1.2,
              1.1,
              1.0,
              1.1,
              1.2,
              1.4,
              2.4,
              2.5,
              2.5,
              3.4
            ]
          },
          {
            "name": "Qol",
            "unit": null,
            "values": [
              1.0,
              1.0,
              1.0,
              1.0,
              1.0,
              1.1,
              1.2,
              1.5,
              1.3,
              1.2,
              1.3,
              1.4
            ]
          },
          {
            "name": "Ain",
            "unit": null,
            "values": [
              1.0,
              1.0,
              1.0,
              0.9,
              0.9,
              1.0,
              1.0,
              1.1,
              1.2,
              1.2,
              1.2,
              1.3
            ]
          },
          {
            "name": "MSNW",
            "unit": null,
            "values": [
              1.0,
              1.0,
              1.0,
              1.0,
              0.9,
              0.9,
              1.0,
              0.9,
              1.1,
              1.1,
              1.0,
              1.0
            ]
          }
        ],
        "figure_id": "bf8a4c6ee599fba1",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -20,
              "max": 20
            }
          }
        },
        "series": [
          {
            "name": "Number of Rx",
            "unit": "%",
            "values": [
              6.5,
              8.5,
              6,
              7.5,
              8.5,
              8.5,
              0,
              6.5,
              -4,
              4.5,
              -2,
              -4,
              -1,
              2,
              4.5,
              2,
              -4,
              -6,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Unit price",
            "unit": "%",
            "values": [
              0,
              -2,
              -4,
              -5,
              -3,
              0,
              -1,
              0,
              1,
              0,
              -1,
              0,
              2,
              0,
              0,
              1,
              0,
              0,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "METI",
            "unit": "%",
            "values": [
              17,
              15,
              13,
              11,
              12,
              10,
              5,
              10,
              7,
              11,
              9,
              6,
              12,
              11,
              12,
              10,
              6,
              4,
              11,
              13,
              14,
              13,
              null
            ]
          }
        ],
        "figure_id": "c1cc1c30e35f0d25",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-23",
              "Oct-23",
              "Dec-23",
              "Feb-24",
              "Apr-24",
              "Jun-24",
              "Aug-24",
              "Oct-24",
              "Dec-24",
              "Feb-25",
              "Apr-25",
              "Jun-25"
            ]
          },
          "y": {
            "left": {
              "unit": "Â¥tn",
              "range": {
                "min": 35.0,
                "max": 55.0
              }
            },
            "right": {
              "unit": "%",
              "range": {
                "min": 3.5,
                "max": 5.5
              }
            }
          }
        },
        "series": [
          {
            "name": "PHRM",
            "unit": "Â¥tn",
            "values": [
              42.5,
              40.5,
              41.0,
              44.0,
              42.0,
              43.0,
              50.5,
              47.0,
              44.0,
              42.0,
              37.0,
              43.0
            ]
          },
          {
            "name": "PHRM vs TOPIX (Market cap)",
            "unit": "%",
            "values": [
              5.1,
              4.9,
              4.8,
              4.6,
              4.4,
              4.4,
              5.3,
              4.8,
              4.5,
              4.3,
              4.7,
              3.9
            ]
          }
        ],
        "figure_id": "713f32a20844986a",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -20,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "OTC drug, left",
            "unit": "%",
            "values": [
              8,
              13,
              8,
              -5,
              8,
              -2,
              -1,
              2,
              -1,
              0,
              -5,
              -7,
              -4,
              0,
              -1,
              7,
              -1,
              -5,
              -1,
              -2,
              -1,
              0,
              -1
            ]
          },
          {
            "name": "Prescription drug, left",
            "unit": "%",
            "values": [
              7,
              8,
              2,
              1,
              12,
              8,
              -1,
              7,
              -1,
              12,
              -2,
              -1,
              6,
              7,
              4,
              8,
              -3,
              -1,
              5,
              3,
              2,
              9,
              12
            ]
          },
          {
            "name": "Kyokai Kenpo Gx share right",
            "unit": "%",
            "values": [
              83,
              83.5,
              84,
              84,
              84.5,
              84,
              84.5,
              85,
              85.5,
              86,
              86.5,
              87,
              88,
              88.5,
              89,
              89,
              88.5,
              88.5,
              88.5,
              88.5,
              88.5,
              88.5,
              88.5
            ]
          }
        ],
        "figure_id": "b94706e3bd2d52f2",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 14,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.8,
              "max": 1.3
            }
          }
        },
        "series": [
          {
            "name": "Towa",
            "unit": null,
            "values": [
              1.0,
              1.02,
              1.04,
              1.06,
              1.08,
              1.1,
              1.09,
              1.08,
              1.1,
              1.09,
              1.08,
              1.0,
              0.98,
              0.98,
              1.0,
              1.02,
              1.08,
              1.17,
              1.17,
              1.15,
              1.1,
              1.05,
              1.0,
              0.95,
              0.9,
              0.85,
              0.88,
              0.92,
              0.95,
              0.98,
              1.0,
              1.05,
              1.08,
              1.1,
              1.12,
              1.15,
              1.18,
              1.15,
              1.05,
              1.0,
              1.02,
              1.04
            ]
          },
          {
            "name": "Sawai",
            "unit": null,
            "values": [
              1.02,
              1.04,
              0.98,
              1.02,
              1.05,
              1.0,
              0.98,
              0.95,
              0.92,
              0.98,
              1.08,
              1.05,
              1.08,
              1.0,
              0.95,
              0.9,
              0.98,
              1.02,
              1.05,
              1.0,
              0.95,
              0.9,
              0.85,
              0.9,
              0.95,
              1.0,
              1.02,
              0.98,
              0.9,
              0.85,
              0.8,
              0.88,
              0.92,
              0.95,
              0.98,
              1.0,
              1.02,
              1.05,
              1.08,
              1.05,
              1.02,
              0.98
            ]
          }
        ],
        "figure_id": "8b05b9e85040fb50",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -30,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "Surgery",
            "unit": "%",
            "values": [
              -3,
              -1,
              -5,
              -4,
              -4,
              -1,
              -5,
              1,
              1,
              -7,
              7,
              -1,
              -1,
              3,
              4,
              3,
              0,
              -9,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Orthopedics",
            "unit": "%",
            "values": [
              3,
              4,
              1,
              3,
              5,
              3,
              -1,
              3,
              7,
              2,
              -1,
              -1,
              0,
              1,
              1,
              0,
              2,
              -1,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Dermatology",
            "unit": "%",
            "values": [
              4,
              5,
              2,
              4,
              6,
              4,
              0,
              4,
              6,
              0,
              -1,
              1,
              2,
              3,
              2,
              1,
              5,
              1,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Ophthalmology",
            "unit": "%",
            "values": [
              2,
              3,
              5,
              6,
              6,
              5,
              -3,
              7,
              8,
              3,
              -1,
              -2,
              -1,
              2,
              3,
              4,
              -1,
              -2,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "12544c2aa1cf42b7",
        "provenance": {
          "page": 9
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 9,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "23/9",
              "23/10",
              "23/11",
              "23/12",
              "24/1",
              "24/2",
              "24/3",
              "24/4",
              "24/5",
              "24/6",
              "24/7",
              "24/8",
              "24/9",
              "24/10",
              "24/11",
              "24/12",
              "25/1",
              "25/2",
              "25/3",
              "25/4",
              "25/5",
              "25/6",
              "25/7"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -20,
              "max": 30
            }
          }
        },
        "series": [
          {
            "name": "Hospital",
            "unit": "%",
            "values": [
              3.5,
              1.5,
              2.5,
              0.5,
              3.0,
              1.0,
              -3.0,
              -1.0,
              1.0,
              -0.5,
              4.0,
              0.5,
              1.0,
              4.0,
              3.0,
              4.5,
              2.0,
              0.5,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Clinics",
            "unit": "%",
            "values": [
              2.0,
              0.0,
              -0.5,
              2.0,
              4.0,
              1.0,
              4.5,
              0.0,
              -4.0,
              -0.5,
              -5.0,
              -2.0,
              -6.0,
              -1.0,
              0.0,
              2.0,
              1.0,
              -6.0,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "Preschool children",
            "unit": "%",
            "values": [
              4.0,
              -3.0,
              -5.0,
              -2.0,
              -6.0,
              -7.0,
              -6.5,
              -4.0,
              -6.0,
              -18.0,
              5.0,
              0.0,
              1.0,
              2.0,
              2.5,
              2.0,
              1.5,
              0.0,
              null,
              null,
              null,
              null,
              null
            ]
          },
          {
            "name": "75+ years old",
            "unit": "%",
            "values": [
              5.0,
              3.0,
              4.0,
              2.0,
              5.0,
              3.0,
              5.0,
              2.0,
              4.0,
              1.0,
              8.0,
              3.0,
              4.0,
              5.0,
              4.0,
              6.0,
              5.0,
              4.0,
              null,
              null,
              null,
              null,
              null
            ]
          }
        ],
        "figure_id": "16986c3e2b6ba266",
        "provenance": {
          "page": 9
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "e0bf3f9a562a0159",
        "value": 0.33299999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td></td><td>Up</td><td>Down</td><td></td><td></td></tr><tr><td>1</td><td>Hogy</td><td>33.3%</td><td>1</td><td>Sysmex</td></tr><tr><td>2</td><td>SNBL</td><td>20.6%</td><td>2</td><td>Chuga",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "31a5853a5eb4db06",
        "value": 0.20600000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>1</td><td>Hogy</td><td>33.3%</td><td>1</td><td>Sysmex</td></tr><tr><td>2</td><td>SNBL</td><td>20.6%</td><td>2</td><td>Chugai</td></tr><tr><td>3</td><td>Amvis</td><td>19.6%</td><td>3</td><td>Medl",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e061d8b8ab6217a2",
        "value": 0.196,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>2</td><td>SNBL</td><td>20.6%</td><td>2</td><td>Chugai</td></tr><tr><td>3</td><td>Amvis</td><td>19.6%</td><td>3</td><td>Medley</td></tr><tr><td>4</td><td>M3</td><td>18.8%</td><td>4</td><td>Santen<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c12d3670f752b15f",
        "value": 0.188,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>3</td><td>Amvis</td><td>19.6%</td><td>3</td><td>Medley</td></tr><tr><td>4</td><td>M3</td><td>18.8%</td><td>4</td><td>Santen</td></tr><tr><td>5</td><td>Astellas</td><td>14.6%</td><td>5</td><td>T",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7252d8723cedc97e",
        "value": 0.146,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4</td><td>M3</td><td>18.8%</td><td>4</td><td>Santen</td></tr><tr><td>5</td><td>Astellas</td><td>14.6%</td><td>5</td><td>Towa</td></tr><tr><td>6</td><td>Otsuka</td><td>14.3%</td><td>6</td><td>N.Kod",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "dce739283d50cc8c",
        "value": 0.14300000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5</td><td>Astellas</td><td>14.6%</td><td>5</td><td>Towa</td></tr><tr><td>6</td><td>Otsuka</td><td>14.3%</td><td>6</td><td>N.Koden</td></tr><tr><td>7</td><td>Fujifilm</td><td>13.6%</td><td>7</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "efa6f76083d69d50",
        "value": 0.136,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Otsuka</td><td>14.3%</td><td>6</td><td>N.Koden</td></tr><tr><td>7</td><td>Fujifilm</td><td>13.6%</td><td>7</td><td>Olympus</td></tr><tr><td>8</td><td>PHC</td><td>13.3%</td><td>8</td><td>Sawai",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "41ff17c4bb7d1a9d",
        "value": 0.133,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>7</td><td>Fujifilm</td><td>13.6%</td><td>7</td><td>Olympus</td></tr><tr><td>8</td><td>PHC</td><td>13.3%</td><td>8</td><td>Sawai</td></tr><tr><td>9</td><td>Eisai</td><td>11.9%</td><td>9</td><td>Tryt<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b7af20143a8facd1",
        "value": 0.11900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>8</td><td>PHC</td><td>13.3%</td><td>8</td><td>Sawai</td></tr><tr><td>9</td><td>Eisai</td><td>11.9%</td><td>9</td><td>Tryt</td></tr><tr><td>10</td><td>MDV</td><td>11.9%</td><td>10</td><td>Medpee",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "aadcdc61a115c0db",
        "value": 0.11900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>9</td><td>Eisai</td><td>11.9%</td><td>9</td><td>Tryt</td></tr><tr><td>10</td><td>MDV</td><td>11.9%</td><td>10</td><td>Medpeer</td></tr><tr><td>11</td><td>JMDC</td><td>10.6%</td><td>11</td><td>M",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "df38044803246f90",
        "value": 0.106,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>10</td><td>MDV</td><td>11.9%</td><td>10</td><td>Medpeer</td></tr><tr><td>11</td><td>JMDC</td><td>10.6%</td><td>11</td><td>MSNW</td></tr><tr><td>12</td><td>Nipro</td><td>10.4%</td><td>12</td><td>N.S",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a6b20c2eb7e28f5a",
        "value": 0.10400000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>11</td><td>JMDC</td><td>10.6%</td><td>11</td><td>MSNW</td></tr><tr><td>12</td><td>Nipro</td><td>10.4%</td><td>12</td><td>N.Shinvaku</td></tr><tr><td>13</td><td>Shimadzu</td><td>9.8%</td><td>13</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0ee2bd3cd98e7409",
        "value": 0.098,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Nipro</td><td>10.4%</td><td>12</td><td>N.Shinvaku</td></tr><tr><td>13</td><td>Shimadzu</td><td>9.8%</td><td>13</td><td>Shionogi</td></tr><tr><td>14</td><td>Qol</td><td>9.7%</td><td>14</td><td>Tsu",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e4c81f077ea4664f",
        "value": 0.09699999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>Shimadzu</td><td>9.8%</td><td>13</td><td>Shionogi</td></tr><tr><td>14</td><td>Qol</td><td>9.7%</td><td>14</td><td>Tsuruha</td></tr><tr><td>15</td><td>Toho</td><td>9.0%</td><td>15</td><td>SMS",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "50f416a7ac6fea75",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>14</td><td>Qol</td><td>9.7%</td><td>14</td><td>Tsuruha</td></tr><tr><td>15</td><td>Toho</td><td>9.0%</td><td>15</td><td>SMS</td></tr></table> Source: Bloomberg, BofA Global Research. ## Exhibit 5:",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "533532dfe4ac01ae",
        "value": 0.21600000000000003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td></td><td>Up</td><td>Down</td><td></td><td></td></tr><tr><td>1</td><td>N.chozai</td><td>21.6%</td><td>1</td><td>Amvis</td></tr><tr><td>2</td><td>Tryt</td><td>94.7%</td><td>2</td><td>Nxera<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "22cd73b8ffbc79df",
        "value": 0.9470000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1</td><td>N.chozai</td><td>21.6%</td><td>1</td><td>Amvis</td></tr><tr><td>2</td><td>Tryt</td><td>94.7%</td><td>2</td><td>Nxera</td></tr><tr><td>3</td><td>M3</td><td>57.3%</td><td>3</td><td>D.Sankyo",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a5028db5d0afe0fc",
        "value": 0.573,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>2</td><td>Tryt</td><td>94.7%</td><td>2</td><td>Nxera</td></tr><tr><td>3</td><td>M3</td><td>57.3%</td><td>3</td><td>D.Sankyo</td></tr><tr><td>4</td><td>Sugi</td><td>57.0%</td><td>4</td><td>Oly",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a6a005a20eb8948b",
        "value": 0.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>3</td><td>M3</td><td>57.3%</td><td>3</td><td>D.Sankyo</td></tr><tr><td>4</td><td>Sugi</td><td>57.0%</td><td>4</td><td>Olympus</td></tr><tr><td>5</td><td>Qol</td><td>48.5%</td><td>5</td><td>Sysme",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "220dd50a255077d0",
        "value": 0.485,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>4</td><td>Sugi</td><td>57.0%</td><td>4</td><td>Olympus</td></tr><tr><td>5</td><td>Qol</td><td>48.5%</td><td>5</td><td>Sysmex</td></tr><tr><td>6</td><td>SNBL</td><td>44.4%</td><td>6</td><td>SMS</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c2924f26e710edea",
        "value": 0.444,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>5</td><td>Qol</td><td>48.5%</td><td>5</td><td>Sysmex</td></tr><tr><td>6</td><td>SNBL</td><td>44.4%</td><td>6</td><td>SMS</td></tr><tr><td>7</td><td>Tsuruha</td><td>31.6%</td><td>7</td><td>Ono</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2d67e2bfc989c1d3",
        "value": 0.316,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>6</td><td>SNBL</td><td>44.4%</td><td>6</td><td>SMS</td></tr><tr><td>7</td><td>Tsuruha</td><td>31.6%</td><td>7</td><td>Ono</td></tr><tr><td>8</td><td>HUG</td><td>30.6%</td><td>8</td><td>Eisai</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cf24ce1afa7f4003",
        "value": 0.306,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>7</td><td>Tsuruha</td><td>31.6%</td><td>7</td><td>Ono</td></tr><tr><td>8</td><td>HUG</td><td>30.6%</td><td>8</td><td>Eisai</td></tr><tr><td>9</td><td>Welcia</td><td>29.1%</td><td>9</td><td>Shim",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "01398a430f0a6145",
        "value": 0.29100000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>8</td><td>HUG</td><td>30.6%</td><td>8</td><td>Eisai</td></tr><tr><td>9</td><td>Welcia</td><td>29.1%</td><td>9</td><td>Shimadzu</td></tr><tr><td>10</td><td>Hogy</td><td>21.4%</td><td>10</td><td>M",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "a43dbe4cd2c57e3a",
        "value": 0.214,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">9</td><td>Welcia</td><td>29.1%</td><td>9</td><td>Shimadzu</td></tr><tr><td>10</td><td>Hogy</td><td>21.4%</td><td>10</td><td>Medley</td></tr><tr><td>11</td><td>Nipro</td><td>18.5%</td><td>11</td><td>K",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c3cc016268eae09b",
        "value": 0.185,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>10</td><td>Hogy</td><td>21.4%</td><td>10</td><td>Medley</td></tr><tr><td>11</td><td>Nipro</td><td>18.5%</td><td>11</td><td>K.Kirin</td></tr><tr><td>12</td><td>Ain</td><td>18.1%</td><td>12</td><td>N.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "be3e72d76109e7cf",
        "value": 0.18100000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>11</td><td>Nipro</td><td>18.5%</td><td>11</td><td>K.Kirin</td></tr><tr><td>12</td><td>Ain</td><td>18.1%</td><td>12</td><td>N.Koden</td></tr><tr><td>13</td><td>Toho</td><td>17.5%</td><td>13</td><td>S",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "003849b2c362bd66",
        "value": 0.175,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>12</td><td>Ain</td><td>18.1%</td><td>12</td><td>N.Koden</td></tr><tr><td>13</td><td>Toho</td><td>17.5%</td><td>13</td><td>Santen</td></tr><tr><td>14</td><td>Shionogi</td><td>16.4%</td><td>14</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4f15aa328de0e0bc",
        "value": 0.16399999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>Toho</td><td>17.5%</td><td>13</td><td>Santen</td></tr><tr><td>14</td><td>Shionogi</td><td>16.4%</td><td>14</td><td>Chugai</td></tr><tr><td>15</td><td>TOPIX</td><td>15.5%</td><td>15</td><td>P",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "897810d905dd980a",
        "value": 0.155,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Shionogi</td><td>16.4%</td><td>14</td><td>Chugai</td></tr><tr><td>15</td><td>TOPIX</td><td>15.5%</td><td>15</td><td>PHC</td></tr></table> Source: Bloomberg, BofA Global Research. BofA GLOBAL ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cf446f3860d38f39",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>4568</td><td>D-Sankyo</td><td>Q1</td><td>463,300</td><td>79,900</td><td>474,597</td><td>9%</td><td>24%</td><td>96,300</td><td>32%</td><td>28%</td></tr><tr><td rowspan=\"3\">4578</td><td rows",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "262ba8b16d17edea",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">4568</td><td>D-Sankyo</td><td>Q1</td><td>463,300</td><td>79,900</td><td>474,597</td><td>9%</td><td>24%</td><td>96,300</td><td>32%</td><td>28%</td></tr><tr><td rowspan=\"3\">4578</td><td rowspan=\"3\">Ots",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4e2680fa21ec4df7",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Q1</td><td>463,300</td><td>79,900</td><td>474,597</td><td>9%</td><td>24%</td><td>96,300</td><td>32%</td><td>28%</td></tr><tr><td rowspan=\"3\">4578</td><td rowspan=\"3\">Otsuka Holdings</td><td>Q2</td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "295943c8a0b3d316",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>463,300</td><td>79,900</td><td>474,597</td><td>9%</td><td>24%</td><td>96,300</td><td>32%</td><td>28%</td></tr><tr><td rowspan=\"3\">4578</td><td rowspan=\"3\">Otsuka Holdings</td><td>Q2</td><td>597,200",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "43eb9f204770510e",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td rowspan=\"3\">Otsuka Holdings</td><td>Q2</td><td>597,200</td><td>116,100</td><td>597,926</td><td>1%</td><td>25%</td><td>119,500</td><td>-4%</td><td>30%</td></tr><tr><td>6M</td><td>1,180,000</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8a7ab4c3aa86f19e",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n=\"3\">Otsuka Holdings</td><td>Q2</td><td>597,200</td><td>116,100</td><td>597,926</td><td>1%</td><td>25%</td><td>119,500</td><td>-4%</td><td>30%</td></tr><tr><td>6M</td><td>1,180,000</td><td>239,000</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4bd1b649f64c02e7",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Q2</td><td>597,200</td><td>116,100</td><td>597,926</td><td>1%</td><td>25%</td><td>119,500</td><td>-4%</td><td>30%</td></tr><tr><td>6M</td><td>1,180,000</td><td>239,000</td><td>1,180,766</td><td>6%</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "69da912a32ea104c",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">597,200</td><td>116,100</td><td>597,926</td><td>1%</td><td>25%</td><td>119,500</td><td>-4%</td><td>30%</td></tr><tr><td>6M</td><td>1,180,000</td><td>239,000</td><td>1,180,766</td><td>6%</td><td>50%</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ece4d4674b07c446",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-4%</td><td>30%</td></tr><tr><td>6M</td><td>1,180,000</td><td>239,000</td><td>1,180,766</td><td>6%</td><td>50%</td><td>239,200</td><td>12%</td><td>60%</td></tr><tr><td></td><td></td><td></td><td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a4de9d60174e4ca1",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>30%</td></tr><tr><td>6M</td><td>1,180,000</td><td>239,000</td><td>1,180,766</td><td>6%</td><td>50%</td><td>239,200</td><td>12%</td><td>60%</td></tr><tr><td></td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2fa719e29c62e887",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1,180,000</td><td>239,000</td><td>1,180,766</td><td>6%</td><td>50%</td><td>239,200</td><td>12%</td><td>60%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3ad4c28d919c2d63",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "80,000</td><td>239,000</td><td>1,180,766</td><td>6%</td><td>50%</td><td>239,200</td><td>12%</td><td>60%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "880cd2fc566336e0",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>4151</td><td>Kyowa Kirin</td><td>Q2</td><td>128,800</td><td>26,300</td><td>125,929</td><td>-1%</td><td>26%</td><td>26,400</td><td>-1%</td><td>33%</td></tr><tr><td></td><td></td><td>6M</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0c351d11a98019c0",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>Kyowa Kirin</td><td>Q2</td><td>128,800</td><td>26,300</td><td>125,929</td><td>-1%</td><td>26%</td><td>26,400</td><td>-1%</td><td>33%</td></tr><tr><td></td><td></td><td>6M</td><td>233,500</td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6bb308e0c7d2f314",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Q2</td><td>128,800</td><td>26,300</td><td>125,929</td><td>-1%</td><td>26%</td><td>26,400</td><td>-1%</td><td>33%</td></tr><tr><td></td><td></td><td>6M</td><td>233,500</td><td>34,900</td><td>230,654",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7ae5281f41f3ee17",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>128,800</td><td>26,300</td><td>125,929</td><td>-1%</td><td>26%</td><td>26,400</td><td>-1%</td><td>33%</td></tr><tr><td></td><td></td><td>6M</td><td>233,500</td><td>34,900</td><td>230,654</td><td>-1%",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "29b0aa4dcb36769e",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>33%</td></tr><tr><td></td><td></td><td>6M</td><td>233,500</td><td>34,900</td><td>230,654</td><td>-1%</td><td>48%</td><td>35,000</td><td>-21%</td><td>44%</td></tr><tr><td>4502</td><td>Takeda</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0d0cb985cf11fa40",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td></td><td></td><td>6M</td><td>233,500</td><td>34,900</td><td>230,654</td><td>-1%</td><td>48%</td><td>35,000</td><td>-21%</td><td>44%</td></tr><tr><td>4502</td><td>Takeda</td><td>Q1</td><td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2e945e489611191a",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>6M</td><td>233,500</td><td>34,900</td><td>230,654</td><td>-1%</td><td>48%</td><td>35,000</td><td>-21%</td><td>44%</td></tr><tr><td>4502</td><td>Takeda</td><td>Q1</td><td>1,161,800</td><td>306,600</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c3ef6f83cf09956e",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">233,500</td><td>34,900</td><td>230,654</td><td>-1%</td><td>48%</td><td>35,000</td><td>-21%</td><td>44%</td></tr><tr><td>4502</td><td>Takeda</td><td>Q1</td><td>1,161,800</td><td>306,600</td><td>1,106,",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "deac5c85254022e2",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>4502</td><td>Takeda</td><td>Q1</td><td>1,161,800</td><td>306,600</td><td>1,106,685</td><td>-8%</td><td>24%</td><td>321,800</td><td>-16%</td><td>28%</td></tr><tr><td>4536</td><td>Santen</td><t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4a6ed765137ce064",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>Takeda</td><td>Q1</td><td>1,161,800</td><td>306,600</td><td>1,106,685</td><td>-8%</td><td>24%</td><td>321,800</td><td>-16%</td><td>28%</td></tr><tr><td>4536</td><td>Santen</td><td>Q1</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a4e64489da8e3cb0",
        "value": -0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1,161,800</td><td>306,600</td><td>1,106,685</td><td>-8%</td><td>24%</td><td>321,800</td><td>-16%</td><td>28%</td></tr><tr><td>4536</td><td>Santen</td><td>Q1</td><td>72,700</td><td>13,600</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a9995598b5d58192",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",800</td><td>306,600</td><td>1,106,685</td><td>-8%</td><td>24%</td><td>321,800</td><td>-16%</td><td>28%</td></tr><tr><td>4536</td><td>Santen</td><td>Q1</td><td>72,700</td><td>13,600</td><td>68,737</td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7511efa20a84642d",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>4536</td><td>Santen</td><td>Q1</td><td>72,700</td><td>13,600</td><td>68,737</td><td>-8%</td><td>23%</td><td>9,700</td><td>-39%</td><td>18%</td></tr><tr><td>4507</td><td>Shionogi</td><t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "34bf79884ed890ce",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4536</td><td>Santen</td><td>Q1</td><td>72,700</td><td>13,600</td><td>68,737</td><td>-8%</td><td>23%</td><td>9,700</td><td>-39%</td><td>18%</td></tr><tr><td>4507</td><td>Shionogi</td><td>Q1</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "d2a511f98b201595",
        "value": -0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Q1</td><td>72,700</td><td>13,600</td><td>68,737</td><td>-8%</td><td>23%</td><td>9,700</td><td>-39%</td><td>18%</td></tr><tr><td>4507</td><td>Shionogi</td><td>Q1</td><td>104,400</td><td>30,600</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e9b3d2296faa4346",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>72,700</td><td>13,600</td><td>68,737</td><td>-8%</td><td>23%</td><td>9,700</td><td>-39%</td><td>18%</td></tr><tr><td>4507</td><td>Shionogi</td><td>Q1</td><td>104,400</td><td>30,600</td><td>99,781<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7f93c85477af8cf7",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>4507</td><td>Shionogi</td><td>Q1</td><td>104,400</td><td>30,600</td><td>99,781</td><td>2%</td><td>19%</td><td>35,100</td><td>25%</td><td>20%</td></tr><tr><td rowspan=\"2\">4565</td><td rows",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b291e90691b44a64",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>4507</td><td>Shionogi</td><td>Q1</td><td>104,400</td><td>30,600</td><td>99,781</td><td>2%</td><td>19%</td><td>35,100</td><td>25%</td><td>20%</td></tr><tr><td rowspan=\"2\">4565</td><td rowspan=\"2\">Nxe",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "39f9c06968836ffa",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Q1</td><td>104,400</td><td>30,600</td><td>99,781</td><td>2%</td><td>19%</td><td>35,100</td><td>25%</td><td>20%</td></tr><tr><td rowspan=\"2\">4565</td><td rowspan=\"2\">Nxera</td><td>Q2</td><td>N/A</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "69e19b7b9312d560",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>104,400</td><td>30,600</td><td>99,781</td><td>2%</td><td>19%</td><td>35,100</td><td>25%</td><td>20%</td></tr><tr><td rowspan=\"2\">4565</td><td rowspan=\"2\">Nxera</td><td>Q2</td><td>N/A</td><td>N/A</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ef0998f17b3ddbc3",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rowspan=\"2\">4565</td><td rowspan=\"2\">Nxera</td><td>Q2</td><td>N/A</td><td>N/A</td><td>8,450</td><td>4%</td><td>-</td><td>989</td><td>-53%</td><td>-</td></tr><tr><td>6M</td><td>N/A</td><td>N/A</td><td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "14a017f07b5f3cfb",
        "value": -0.53,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "\"2\">Nxera</td><td>Q2</td><td>N/A</td><td>N/A</td><td>8,450</td><td>4%</td><td>-</td><td>989</td><td>-53%</td><td>-</td></tr><tr><td>6M</td><td>N/A</td><td>N/A</td><td>15,094</td><td>19%</td><td>-</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ca0f8b5de552e30e",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>989</td><td>-53%</td><td>-</td></tr><tr><td>6M</td><td>N/A</td><td>N/A</td><td>15,094</td><td>19%</td><td>-</td><td>364</td><td>-69%</td><td>-</td></tr><tr><td>4519</td><td>Chugai</td><td>Q2</td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "605dbbc324947551",
        "value": -0.69,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>6M</td><td>N/A</td><td>N/A</td><td>15,094</td><td>19%</td><td>-</td><td>364</td><td>-69%</td><td>-</td></tr><tr><td>4519</td><td>Chugai</td><td>Q2</td><td>294,400</td><td>146,500</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "9e33516d61aa7bbd",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>4519</td><td>Chugai</td><td>Q2</td><td>294,400</td><td>146,500</td><td>290,005</td><td>-8%</td><td>24%</td><td>132,500</td><td>-17%</td><td>23%</td></tr><tr><td></td><td></td><td>6M</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "644a74123c5a234f",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">4519</td><td>Chugai</td><td>Q2</td><td>294,400</td><td>146,500</td><td>290,005</td><td>-8%</td><td>24%</td><td>132,500</td><td>-17%</td><td>23%</td></tr><tr><td></td><td></td><td>6M</td><td>582,900</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "52d2495ff0836504",
        "value": -0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Q2</td><td>294,400</td><td>146,500</td><td>290,005</td><td>-8%</td><td>24%</td><td>132,500</td><td>-17%</td><td>23%</td></tr><tr><td></td><td></td><td>6M</td><td>582,900</td><td>286,000</td><td>578,4",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f03b4712849a813b",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "94,400</td><td>146,500</td><td>290,005</td><td>-8%</td><td>24%</td><td>132,500</td><td>-17%</td><td>23%</td></tr><tr><td></td><td></td><td>6M</td><td>582,900</td><td>286,000</td><td>578,464</td><td>5%",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "584e507057160a59",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>23%</td></tr><tr><td></td><td></td><td>6M</td><td>582,900</td><td>286,000</td><td>578,464</td><td>5%</td><td>49%</td><td>272,000</td><td>4%</td><td>48%</td></tr><tr><td>4503</td><td>Astellas</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ee7c2212fd23098f",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td></td><td></td><td>6M</td><td>582,900</td><td>286,000</td><td>578,464</td><td>5%</td><td>49%</td><td>272,000</td><td>4%</td><td>48%</td></tr><tr><td>4503</td><td>Astellas</td><td>Q1</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "06b016ff550d0be1",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>6M</td><td>582,900</td><td>286,000</td><td>578,464</td><td>5%</td><td>49%</td><td>272,000</td><td>4%</td><td>48%</td></tr><tr><td>4503</td><td>Astellas</td><td>Q1</td><td>468,500</td><td>94,500</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4c06adfe0ac15f1a",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>582,900</td><td>286,000</td><td>578,464</td><td>5%</td><td>49%</td><td>272,000</td><td>4%</td><td>48%</td></tr><tr><td>4503</td><td>Astellas</td><td>Q1</td><td>468,500</td><td>94,500</td><td>505,794",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c6ddd3fbfe6f238f",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>4503</td><td>Astellas</td><td>Q1</td><td>468,500</td><td>94,500</td><td>505,794</td><td>7%</td><td>26%</td><td>142,300</td><td>61%</td><td>35%</td></tr><tr><td>4528</td><td>Ono Pharm.</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e6cf62af369d47a6",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">4503</td><td>Astellas</td><td>Q1</td><td>468,500</td><td>94,500</td><td>505,794</td><td>7%</td><td>26%</td><td>142,300</td><td>61%</td><td>35%</td></tr><tr><td>4528</td><td>Ono Pharm.</td><td>Q1</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "59574122895b8a46",
        "value": 0.61,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Q1</td><td>468,500</td><td>94,500</td><td>505,794</td><td>7%</td><td>26%</td><td>142,300</td><td>61%</td><td>35%</td></tr><tr><td>4528</td><td>Ono Pharm.</td><td>Q1</td><td>118,700</td><td>30,700</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3d2fcd6b2d56e945",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>468,500</td><td>94,500</td><td>505,794</td><td>7%</td><td>26%</td><td>142,300</td><td>61%</td><td>35%</td></tr><tr><td>4528</td><td>Ono Pharm.</td><td>Q1</td><td>118,700</td><td>30,700</td><td>127,5",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "50cd801bf92a0fd3",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>4528</td><td>Ono Pharm.</td><td>Q1</td><td>118,700</td><td>30,700</td><td>127,536</td><td>8%</td><td>26%</td><td>31,600</td><td>-10%</td><td>28%</td></tr><tr><td>4523</td><td>Eisai</td><td>Q",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f50186c25143a7fe",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "528</td><td>Ono Pharm.</td><td>Q1</td><td>118,700</td><td>30,700</td><td>127,536</td><td>8%</td><td>26%</td><td>31,600</td><td>-10%</td><td>28%</td></tr><tr><td>4523</td><td>Eisai</td><td>Q1</td><td>1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "232708d8653725ec",
        "value": -0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>237,600</td><td>218,600</td><td>26,390</td><td>34,312</td><td>20,603</td><td>206,512</td><td>-12%</td><td>21%</td><td>16,351</td><td>-41%</td></tr><tr><td>4543</td><td>Terumo</td><td>Q1</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c8c7580b5d3374c2",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>218,600</td><td>26,390</td><td>34,312</td><td>20,603</td><td>206,512</td><td>-12%</td><td>21%</td><td>16,351</td><td>-41%</td></tr><tr><td>4543</td><td>Terumo</td><td>Q1</td><td>262,556</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3f5ceaa18d533670",
        "value": -0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6,390</td><td>34,312</td><td>20,603</td><td>206,512</td><td>-12%</td><td>21%</td><td>16,351</td><td>-41%</td></tr><tr><td>4543</td><td>Terumo</td><td>Q1</td><td>262,556</td><td>268,100</td><td>258,000",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "757739156be1907c",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>268,100</td><td>258,000</td><td>47,177</td><td>50,000</td><td>42,845</td><td>259,965</td><td>1%</td><td>25%</td><td>55,885</td><td>25%</td></tr><tr><td>6869</td><td>Sysmex</td><td>Q1</td><td>11",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "12b7625302c6e9ff",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "100</td><td>258,000</td><td>47,177</td><td>50,000</td><td>42,845</td><td>259,965</td><td>1%</td><td>25%</td><td>55,885</td><td>25%</td></tr><tr><td>6869</td><td>Sysmex</td><td>Q1</td><td>117,435</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "2fca3aa90bf3dc77",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">47,177</td><td>50,000</td><td>42,845</td><td>259,965</td><td>1%</td><td>25%</td><td>55,885</td><td>25%</td></tr><tr><td>6869</td><td>Sysmex</td><td>Q1</td><td>117,435</td><td>121,900</td><td>113,400<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "fffd017115c0cd76",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>121,900</td><td>113,400</td><td>17,965</td><td>29,500</td><td>22,220</td><td>105,731</td><td>-6%</td><td>20%</td><td>10,628</td><td>-37%</td></tr><tr><td>7747</td><td>Asahi Intec</td><td>Q4</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e5e2217dda002d96",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "00</td><td>113,400</td><td>17,965</td><td>29,500</td><td>22,220</td><td>105,731</td><td>-6%</td><td>20%</td><td>10,628</td><td>-37%</td></tr><tr><td>7747</td><td>Asahi Intec</td><td>Q4</td><td>27,967<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "18935aaa39c81d4c",
        "value": -0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "17,965</td><td>29,500</td><td>22,220</td><td>105,731</td><td>-6%</td><td>20%</td><td>10,628</td><td>-37%</td></tr><tr><td>7747</td><td>Asahi Intec</td><td>Q4</td><td>27,967</td><td>29,140</td><td>27,1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f7ca553a732caa43",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "967</td><td>29,140</td><td>27,183</td><td>3,573</td><td>10,500</td><td>7,469</td><td>28,210</td><td>5%</td><td>24%</td><td>4,364</td><td>76%</td></tr><tr><td></td><td></td><td>12M</td><td>120,025</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f27b699bf3e41a1a",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">29,140</td><td>27,183</td><td>3,573</td><td>10,500</td><td>7,469</td><td>28,210</td><td>5%</td><td>24%</td><td>4,364</td><td>76%</td></tr><tr><td></td><td></td><td>12M</td><td>120,025</td><td>120,955",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "574a09aa022d642a",
        "value": 0.76,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>3,573</td><td>10,500</td><td>7,469</td><td>28,210</td><td>5%</td><td>24%</td><td>4,364</td><td>76%</td></tr><tr><td></td><td></td><td>12M</td><td>120,025</td><td>120,955</td><td>118,998</td><td>3",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3ed6edd84fbc4a7f",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>120,955</td><td>118,998</td><td>30,079</td><td>36,215</td><td>33,184</td><td>120,025</td><td>12%</td><td>101%</td><td>30,079</td><td>36%</td></tr><tr><td>6523</td><td>PHC HD</td><td>Q1</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d412d048447796d9",
        "value": 1.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "55</td><td>118,998</td><td>30,079</td><td>36,215</td><td>33,184</td><td>120,025</td><td>12%</td><td>101%</td><td>30,079</td><td>36%</td></tr><tr><td>6523</td><td>PHC HD</td><td>Q1</td><td>86,542</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "de5cb9a8d7447a2f",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0,079</td><td>36,215</td><td>33,184</td><td>120,025</td><td>12%</td><td>101%</td><td>30,079</td><td>36%</td></tr><tr><td>6523</td><td>PHC HD</td><td>Q1</td><td>86,542</td><td>90,576</td><td>84,500</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "cdd1791df3e382a5",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",542</td><td>90,576</td><td>84,500</td><td>1,807</td><td>7,000</td><td>1,623</td><td>83,856</td><td>-2%</td><td>23%</td><td>3,853</td><td>83%</td></tr><tr><td>4901</td><td>Fujifilm</td><td>Q1</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "24895ef1a57071ac",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">90,576</td><td>84,500</td><td>1,807</td><td>7,000</td><td>1,623</td><td>83,856</td><td>-2%</td><td>23%</td><td>3,853</td><td>83%</td></tr><tr><td>4901</td><td>Fujifilm</td><td>Q1</td><td>758,524</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ea4e46d2de517291",
        "value": 0.83,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>1,807</td><td>7,000</td><td>1,623</td><td>83,856</td><td>-2%</td><td>23%</td><td>3,853</td><td>83%</td></tr><tr><td>4901</td><td>Fujifilm</td><td>Q1</td><td>758,524</td><td>766,800</td><td>748,00",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "be740395247908f0",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>766,800</td><td>748,000</td><td>69,552</td><td>83,670</td><td>72,500</td><td>749,482</td><td>0%</td><td>23%</td><td>75,291</td><td>21%</td></tr><tr><td>7701</td><td>Shimadzu</td><td>Q1</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0be6a4a485683853",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "800</td><td>748,000</td><td>69,552</td><td>83,670</td><td>72,500</td><td>749,482</td><td>0%</td><td>23%</td><td>75,291</td><td>21%</td></tr><tr><td>7701</td><td>Shimadzu</td><td>Q1</td><td>117,770</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9c5be3bda451e55d",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">69,552</td><td>83,670</td><td>72,500</td><td>749,482</td><td>0%</td><td>23%</td><td>75,291</td><td>21%</td></tr><tr><td>7701</td><td>Shimadzu</td><td>Q1</td><td>117,770</td><td>120,700</td><td>112,90",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "42f3a074c173667f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>120,700</td><td>112,900</td><td>12,271</td><td>19,800</td><td>17,007</td><td>118,370</td><td>1%</td><td>23%</td><td>12,184</td><td>11%</td></tr></table> Source: BofA Global Research and Bloombe",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1835cf7466262527",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "700</td><td>112,900</td><td>12,271</td><td>19,800</td><td>17,007</td><td>118,370</td><td>1%</td><td>23%</td><td>12,184</td><td>11%</td></tr></table> Source: BofA Global Research and Bloomberg consensu",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f5d3829eb3f82600",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">12,271</td><td>19,800</td><td>17,007</td><td>118,370</td><td>1%</td><td>23%</td><td>12,184</td><td>11%</td></tr></table> Source: BofA Global Research and Bloomberg consensus. FY CoE: Full year Compan",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "79697f697388f519",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>87,600</td><td>83,000</td><td>17,790</td><td>17,000</td><td>13,620</td><td>86,200</td><td>34%</td><td>24%</td><td>18,735</td><td>16%</td></tr><tr><td>4483</td><td>JMDC</td><td>Q1</td><td>9,7",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bc075465d8350538",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",600</td><td>83,000</td><td>17,790</td><td>17,000</td><td>13,620</td><td>86,200</td><td>34%</td><td>24%</td><td>18,735</td><td>16%</td></tr><tr><td>4483</td><td>JMDC</td><td>Q1</td><td>9,747</td><td>1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "88b752594ac56e4f",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">17,790</td><td>17,000</td><td>13,620</td><td>86,200</td><td>34%</td><td>24%</td><td>18,735</td><td>16%</td></tr><tr><td>4483</td><td>JMDC</td><td>Q1</td><td>9,747</td><td>10,080</td><td>9,180</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6fb715f3ca39b81e",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9,747</td><td>10,080</td><td>9,180</td><td>1,330</td><td>2,800</td><td>2,200</td><td>10,725</td><td>32%</td><td>21%</td><td>1,552</td><td>49%</td></tr><tr><td>2175</td><td>SMS</td><td>Q1</td><td>19,17",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "20a81f49cbe66a21",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>10,080</td><td>9,180</td><td>1,330</td><td>2,800</td><td>2,200</td><td>10,725</td><td>32%</td><td>21%</td><td>1,552</td><td>49%</td></tr><tr><td>2175</td><td>SMS</td><td>Q1</td><td>19,171</td><td>19",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "56daa7a4bd30ee95",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>1,330</td><td>2,800</td><td>2,200</td><td>10,725</td><td>32%</td><td>21%</td><td>1,552</td><td>49%</td></tr><tr><td>2175</td><td>SMS</td><td>Q1</td><td>19,171</td><td>19,706</td><td>18,747</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "eae17c03dacc79e6",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "19,171</td><td>19,706</td><td>18,747</td><td>3,525</td><td>1,084</td><td>125</td><td>18,672</td><td>7%</td><td>28%</td><td>3,616</td><td>21%</td></tr><tr><td>4480</td><td>Medley</td><td>Q2</td><td>11,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c125f1e2cefad306",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19,706</td><td>18,747</td><td>3,525</td><td>1,084</td><td>125</td><td>18,672</td><td>7%</td><td>28%</td><td>3,616</td><td>21%</td></tr><tr><td>4480</td><td>Medley</td><td>Q2</td><td>11,176</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "333cb7aa85a4f251",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>3,525</td><td>1,084</td><td>125</td><td>18,672</td><td>7%</td><td>28%</td><td>3,616</td><td>21%</td></tr><tr><td>4480</td><td>Medley</td><td>Q2</td><td>11,176</td><td>12,090</td><td>10,333</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "003c692a7b3847e6",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>11,176</td><td>12,090</td><td>10,333</td><td>2,352</td><td>921</td><td>94</td><td>10,325</td><td>18%</td><td>26%</td><td>1,582</td><td>-21%</td></tr><tr><td></td><td></td><td>6M</td><td>18,465</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d0192c8a185a10f4",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>12,090</td><td>10,333</td><td>2,352</td><td>921</td><td>94</td><td>10,325</td><td>18%</td><td>26%</td><td>1,582</td><td>-21%</td></tr><tr><td></td><td></td><td>6M</td><td>18,465</td><td>20,230</",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a95ad7f8aa48d56b",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>2,352</td><td>921</td><td>94</td><td>10,325</td><td>18%</td><td>26%</td><td>1,582</td><td>-21%</td></tr><tr><td></td><td></td><td>6M</td><td>18,465</td><td>20,230</td><td>18,473</td><td>1,46",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "17080dcf90d157d6",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",465</td><td>20,230</td><td>18,473</td><td>1,461</td><td>9,061</td><td>8,234</td><td>18,465</td><td>26%</td><td>46%</td><td>1,461</td><td>-35%</td></tr><tr><td>Other healthcare service</td><td></td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "863e91b13d87dd28",
        "value": 0.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">20,230</td><td>18,473</td><td>1,461</td><td>9,061</td><td>8,234</td><td>18,465</td><td>26%</td><td>46%</td><td>1,461</td><td>-35%</td></tr><tr><td>Other healthcare service</td><td></td><td></td><td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e505d738cc6691cc",
        "value": -0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>1,461</td><td>9,061</td><td>8,234</td><td>18,465</td><td>26%</td><td>46%</td><td>1,461</td><td>-35%</td></tr><tr><td>Other healthcare service</td><td></td><td></td><td></td><td></td><td></td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "edb37eb7ea12b197",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>938,015</td><td>930,900</td><td>12,898</td><td>13,194</td><td>9,307</td><td>945,159</td><td>4%</td><td>25%</td><td>14,053</td><td>6%</td></tr><tr><td>4887</td><td>Sawai GHD</td><td>Q1</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "90d36cec411e499e",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",015</td><td>930,900</td><td>12,898</td><td>13,194</td><td>9,307</td><td>945,159</td><td>4%</td><td>25%</td><td>14,053</td><td>6%</td></tr><tr><td>4887</td><td>Sawai GHD</td><td>Q1</td><td>48,243</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7cf08aa445d86d2c",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>12,898</td><td>13,194</td><td>9,307</td><td>945,159</td><td>4%</td><td>25%</td><td>14,053</td><td>6%</td></tr><tr><td>4887</td><td>Sawai GHD</td><td>Q1</td><td>48,243</td><td>49,617</td><td>46,920</",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f6959899f8be8cf6",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",243</td><td>49,617</td><td>46,920</td><td>7,097</td><td>8,490</td><td>5,842</td><td>49,511</td><td>12%</td><td>25%</td><td>6,979</td><td>15%</td></tr><tr><td>9627</td><td>Ain HD</td><td>Q1</td><td>12",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0b19fc717ae27c5d",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">49,617</td><td>46,920</td><td>7,097</td><td>8,490</td><td>5,842</td><td>49,511</td><td>12%</td><td>25%</td><td>6,979</td><td>15%</td></tr><tr><td>9627</td><td>Ain HD</td><td>Q1</td><td>122,931</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6d85b6b19c89fe51",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>7,097</td><td>8,490</td><td>5,842</td><td>49,511</td><td>12%</td><td>25%</td><td>6,979</td><td>15%</td></tr><tr><td>9627</td><td>Ain HD</td><td>Q1</td><td>122,931</td><td>126,500</td><td>117,356<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "0197b5eb117396cc",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>126,500</td><td>117,356</td><td>3,951</td><td>4,500</td><td>3,500</td><td>122,931</td><td>19%</td><td>24%</td><td>3,951</td><td>43%</td></tr></table> Source: BofA Global Research and Bloombe",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e2e7cbe4a49800f4",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6,500</td><td>117,356</td><td>3,951</td><td>4,500</td><td>3,500</td><td>122,931</td><td>19%</td><td>24%</td><td>3,951</td><td>43%</td></tr></table> Source: BofA Global Research and Bloomberg consensus",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "89e5ce4aa4dcf2a0",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>3,951</td><td>4,500</td><td>3,500</td><td>122,931</td><td>19%</td><td>24%</td><td>3,951</td><td>43%</td></tr></table> Source: BofA Global Research and Bloomberg consensus. FY CoE: Full year Compan",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "79697f697388f519",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7</td><td>87,600</td><td>83,000</td><td>17,790</td><td>17,000</td><td>13,620</td><td>86,200</td><td>34%</td><td>24%</td><td>18,735</td><td>16%</td></tr><tr><td>4483</td><td>JMDC</td><td>Q1</td><td>9,7",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bc075465d8350538",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",600</td><td>83,000</td><td>17,790</td><td>17,000</td><td>13,620</td><td>86,200</td><td>34%</td><td>24%</td><td>18,735</td><td>16%</td></tr><tr><td>4483</td><td>JMDC</td><td>Q1</td><td>9,747</td><td>1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7e702ce20b54addf",
        "value": -0.147,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>OWL833(LY-3502970)</td><td>Eli Lilly</td><td>Licensed out</td><td>P2 data readout in ADA (-14.7% weight loss at 36w)</td></tr><tr><td></td><td>OWL833(LY-3502970)</td><td>Novo Nordisk/ amycre",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "aeafa3ff45be7bc3",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Novartis</td><td>Licensed out</td><td>Market expansion based on 2L mCRPC data. Exp'd RR** up to 18%.</td></tr><tr><td>Kisqali</td><td>Novartis</td><td>Licensed out</td><td>Market expansion based o",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "6d538681a12966aa",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Novartis</td><td>Licensed out</td><td>Market expansion based on early BC data. Exp'd RR up to 4%.</td></tr><tr><td>RDN</td><td>Medtronic</td><td>Competitor</td><td></td></tr><tr><td rowspan=\"3\">",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "98d1bf0ab5491f2a",
        "value": -0.147,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Lotiglipron</td><td>Eli Lilly/ orforglipron</td><td>Competitor</td><td>P2 data readout in ADA (-14.7% weight loss at 36w)</td></tr><tr><td colspan=\"5\">Medtech</td></tr><tr><td>Industry</td><td></",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "c238ce2d84a2ed32",
        "value": 20.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "83(rocatinlimab)</td><td>Sanofi/ Dupixent</td><td>Competitor</td><td>Dupixent sales has reached &gt;$20bn</td></tr><tr><td rowspan=\"2\">Shionogi</td><td>HIV products</td><td>GSK/ HIV products</td><td>J",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "e0b6ddbbcc48c092",
        "value": -0.016,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "2b045542b601112a",
        "value": 0.048,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "2b909b27886e5376",
        "value": -0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td></tr><tr><td>Medical spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ff4b571e48d31760",
        "value": -0.011000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td></tr><tr><td>Medical spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><td></td><td></",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "c4d468cf9b45999e",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td></tr><tr><td>Medical spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "c8c984878acbaffe",
        "value": 0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Medical spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "26575409dee11805",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "l spending</td><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medica",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "249d934fe59fdb82",
        "value": 0.028999999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-1.6%</td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical</td><td>-2.",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ad8b277a4ff64628",
        "value": -0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>4.8%</td><td>-0.5%</td><td>-1.1%</td><td>2.5%</td><td>1.8%</td><td>3.3%</td><td>2.9%</td><td>-1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "5d942f98e1029b66",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>2.9%</td><td>-1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "a9a7c86c5f18ba9c",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>-1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "bb0a8176b893cbb9",
        "value": 0.016,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "0565484446d5035e",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td></td><td></td><td></td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td></td><td></t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "9cf9eb92f4ded7d8",
        "value": 0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td><td></td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "1215ff32a93d88ce",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td></td><td></td><td></td><td></td></tr><",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "41a46abc05e5cd61",
        "value": 0.042,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Medical</td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "839dc8def02ae17c",
        "value": 0.027000000000000003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-2.0%</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental</td><td>0.9%",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "e1022c91031bfc45",
        "value": -0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>4.0%</td><td>1.6%</td><td>1.9%</td><td>3.5%</td><td>3.3%</td><td>4.2%</td><td>2.7%</td><td>-1.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "59d3609273759910",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>2.7%</td><td>-1.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "558cb4e2d3a727a3",
        "value": 0.07200000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-1.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "33eaa3af034f0941",
        "value": 0.027999999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "3048c0da5726864b",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td><td></td><td></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td></td><td></td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "d0e67ad113c06eeb",
        "value": 0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "bf8458af147094f8",
        "value": 0.054000000000000006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td></tr><tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "71dbbf6e23f2a9a5",
        "value": 0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Dental</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dispens",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "23e018fac8f7db02",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>0.9%</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dispensing pharmacie",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "520485bfc41fba84",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>7.2%</td><td>2.8%</td><td>2.5%</td><td>4.6%</td><td>5.4%</td><td>1.8%</td><td>3.0%</td><td>1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dispensing pharmacies</td><td>-2.",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "b0956087aed42ae4",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1.7%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Dispensing pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "c0d1903d4a63c8d7",
        "value": 0.059000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td><td></td></tr><tr><td>Dispensing pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "1d71dd077e1c3888",
        "value": -0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td></tr><tr><td>Dispensing pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ab195feed57d4b77",
        "value": -0.031,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td></tr><tr><td>Dispensing pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><td></td><td></",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "9c9bf9365edf9b27",
        "value": 0.036000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Dispensing pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><td></td><td></td><td></td><t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "dfbf0c029d208590",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Dispensing pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><td></td><td></td><td></td><td></td></tr><",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "5efcc7076f056337",
        "value": 0.042,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pharmacies</td><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Home m",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "617455f5942f2f9a",
        "value": 0.027999999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>-2.0%</td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Home medical nursin",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "f5bf9db18cff6366",
        "value": -0.038,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>5.9%</td><td>-1.9%</td><td>-3.1%</td><td>3.6%</td><td>2.1%</td><td>4.2%</td><td>2.8%</td><td>-3.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Home medical nursing</td><td>15.",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "b4b3bd9c0a4b0cb7",
        "value": 0.151,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-3.8%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Home medical nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "260f346ec9e13607",
        "value": 0.22699999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td><td></td><td></td><td></td></tr><tr><td>Home medical nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "791e2317ad19a952",
        "value": 0.192,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td></tr><tr><td>Home medical nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "790d769418c22ba8",
        "value": 0.207,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td></tr><tr><td>Home medical nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></td><td></td><t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "8fe908c319889538",
        "value": 0.182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Home medical nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></td><td></td><td></td><td></t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "5258039355b2ea80",
        "value": 0.185,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Home medical nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></td><td></td><td></td><td></td><td></td></t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "f06483bacb834418",
        "value": 0.183,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nursing</td><td>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medi",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "e41043eccfa37383",
        "value": 0.161,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>15.1%</td><td>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical spending, ",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "62bad32267d23719",
        "value": 0.14300000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>22.7%</td><td>19.2%</td><td>20.7%</td><td>18.2%</td><td>18.5%</td><td>18.3%</td><td>16.1%</td><td>14.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical spending, Adj.</td><td>0",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "39842242fa025ccd",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">14.3%</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical spending, Adj.</td><td>0.9%</td><td>1.7%</td><td>0.4%</td><td>0.7%</td><td>0.9%</td><td>1.8%</td><td>2.9%</td><td>2.1%</td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "b65b2f86a11ac051",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td><td></td></tr><tr><td>Medical spending, Adj.</td><td>0.9%</td><td>1.7%</td><td>0.4%</td><td>0.7%</td><td>0.9%</td><td>1.8%</td><td>2.9%</td><td>2.1%</td><td>1.5%</td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "58a159581fb505d2",
        "value": 0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td></tr><tr><td>Medical spending, Adj.</td><td>0.9%</td><td>1.7%</td><td>0.4%</td><td>0.7%</td><td>0.9%</td><td>1.8%</td><td>2.9%</td><td>2.1%</td><td>1.5%</td><td></td><td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ccd2d0bd78c3e31c",
        "value": 0.006999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td></td></tr><tr><td>Medical spending, Adj.</td><td>0.9%</td><td>1.7%</td><td>0.4%</td><td>0.7%</td><td>0.9%</td><td>1.8%</td><td>2.9%</td><td>2.1%</td><td>1.5%</td><td></td><td></td><td></td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "e8271ab4ff58f1a8",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>Medical spending, Adj.</td><td>0.9%</td><td>1.7%</td><td>0.4%</td><td>0.7%</td><td>0.9%</td><td>1.8%</td><td>2.9%</td><td>2.1%</td><td>1.5%</td><td></td><td></td><td></td><td></td><td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "b7954493c0859356",
        "value": 2.545,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "ame</td><td>Price</td><td>Rating</td></tr><tr><td>KYKOF</td><td>4151 JP</td><td>Kyowa Kirin</td><td>Â¥ 2.545</td><td>B-1-7</td></tr><tr><td>TKPHF</td><td>4502 JP</td><td>Takeda Pharm.</td><td>Â¥ 4.421</",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "5f2a9f0403c0bb41",
        "value": 4.421,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "</td><td>Â¥ 2.545</td><td>B-1-7</td></tr><tr><td>TKPHF</td><td>4502 JP</td><td>Takeda Pharm.</td><td>Â¥ 4.421</td><td>A-1-7</td></tr><tr><td>ALPMF</td><td>4503 JP</td><td>Astellas Pharma</td><td>Â¥ 1.620",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "712f4b3a452cd6e8",
        "value": 1.62,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "td><td>Â¥ 4.421</td><td>A-1-7</td></tr><tr><td>ALPMF</td><td>4503 JP</td><td>Astellas Pharma</td><td>Â¥ 1.620</td><td>B-2-7</td></tr><tr><td>SGIOF</td><td>4507 JP</td><td>Shionogi</td><td>Â¥ 2.550</td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "dd10933476376a29",
        "value": 2.55,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "harma</td><td>Â¥ 1.620</td><td>B-2-7</td></tr><tr><td>SGIOF</td><td>4507 JP</td><td>Shionogi</td><td>Â¥ 2.550</td><td>C-1-7</td></tr><tr><td>CHGCF</td><td>4519 JP</td><td>Chugai Pharm.</td><td>Â¥ 6.509</",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4cfb5d6d2a9d3b4c",
        "value": 6.509,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "</td><td>Â¥ 2.550</td><td>C-1-7</td></tr><tr><td>CHGCF</td><td>4519 JP</td><td>Chugai Pharm.</td><td>Â¥ 6.509</td><td>B-2-7</td></tr><tr><td>ESALF</td><td>4523 JP</td><td>Eisai</td><td>Â¥ 4.538</td><td>B",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "399739e444979f31",
        "value": 4.538,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "i Pharm.</td><td>Â¥ 6.509</td><td>B-2-7</td></tr><tr><td>ESALF</td><td>4523 JP</td><td>Eisai</td><td>Â¥ 4.538</td><td>B-3-7</td></tr><tr><td>OPHLF</td><td>4528 JP</td><td>Ono Pharm.</td><td>Â¥ 1.657</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "0fa7d359c58dc78b",
        "value": 1.657,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "sai</td><td>Â¥ 4.538</td><td>B-3-7</td></tr><tr><td>OPHLF</td><td>4528 JP</td><td>Ono Pharm.</td><td>Â¥ 1.657</td><td>B-3-7</td></tr><tr><td>SNPHF</td><td>4536 JP</td><td>Santen Pharm.</td><td>Â¥ 1.563</",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "382a184c5bcc3701",
        "value": 1.563,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "</td><td>Â¥ 1.657</td><td>B-3-7</td></tr><tr><td>SNPHF</td><td>4536 JP</td><td>Santen Pharm.</td><td>Â¥ 1.563</td><td>B-1-7</td></tr><tr><td>SOLTF</td><td>4565 JP</td><td>Nxera Pharma</td><td>Â¥ 925</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4c2a702ec794b3f5",
        "value": 925.0,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": ".</td><td>Â¥ 1.563</td><td>B-1-7</td></tr><tr><td>SOLTF</td><td>4565 JP</td><td>Nxera Pharma</td><td>Â¥ 925</td><td>C-1-9</td></tr><tr><td>DSKYF</td><td>4568 JP</td><td>Daiichi Sankyo</td><td>Â¥ 3.529</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "12380873901e9628",
        "value": 3.529,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "a</td><td>Â¥ 925</td><td>C-1-9</td></tr><tr><td>DSKYF</td><td>4568 JP</td><td>Daiichi Sankyo</td><td>Â¥ 3.529</td><td>B-1-7</td></tr><tr><td>OTSKF</td><td>4578 JP</td><td>Otsuka Holdings</td><td>Â¥ 7.766",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a21c75c29a28d522",
        "value": 7.766,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "td><td>Â¥ 3.529</td><td>B-1-7</td></tr><tr><td>OTSKF</td><td>4578 JP</td><td>Otsuka Holdings</td><td>Â¥ 7.766</td><td>B-1-7</td></tr><tr><td>TRUMF</td><td>4543 JP</td><td>Terumo</td><td>Â¥ 2.664</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "74400c93cb3bddda",
        "value": 2.664,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "oldings</td><td>Â¥ 7.766</td><td>B-1-7</td></tr><tr><td>TRUMF</td><td>4543 JP</td><td>Terumo</td><td>Â¥ 2.664</td><td>B-1-7</td></tr><tr><td>FUJF</td><td>4901 JP</td><td>Fujifilm Holdings</td><td>Â¥ 3.51",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "6c98e4f9d44d922c",
        "value": 3.511,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "d><td>Â¥ 2.664</td><td>B-1-7</td></tr><tr><td>FUJF</td><td>4901 JP</td><td>Fujifilm Holdings</td><td>Â¥ 3.511</td><td>B-2-7</td></tr><tr><td>PHCCF</td><td>6523 JP</td><td>PHC Holdings</td><td>Â¥ 987</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "52963b07c02df671",
        "value": 987.0,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "s</td><td>Â¥ 3.511</td><td>B-2-7</td></tr><tr><td>PHCCF</td><td>6523 JP</td><td>PHC Holdings</td><td>Â¥ 987</td><td>B-3-8</td></tr><tr><td>SSMXF</td><td>6869 JP</td><td>Sysmex</td><td>Â¥ 1.868</td><td>B-",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "0e904dcd6cc54a60",
        "value": 1.868,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "Holdings</td><td>Â¥ 987</td><td>B-3-8</td></tr><tr><td>SSMXF</td><td>6869 JP</td><td>Sysmex</td><td>Â¥ 1.868</td><td>B-1-7</td></tr><tr><td>SHMZF</td><td>7701 JP</td><td>SHIMADZU</td><td>Â¥ 3.622</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "9f9fc3e3df6b046e",
        "value": 3.622,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "ysmex</td><td>Â¥ 1.868</td><td>B-1-7</td></tr><tr><td>SHMZF</td><td>7701 JP</td><td>SHIMADZU</td><td>Â¥ 3.622</td><td>B-1-7</td></tr><tr><td>OCPNF</td><td>7733 JP</td><td>Olympus Corp.</td><td>Â¥ 1.723</",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4ce38e670b04dfec",
        "value": 1.723,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "</td><td>Â¥ 3.622</td><td>B-1-7</td></tr><tr><td>OCPNF</td><td>7733 JP</td><td>Olympus Corp.</td><td>Â¥ 1.723</td><td>B-2-7</td></tr><tr><td>AHICF</td><td>7747 JP</td><td>Asahi Intec</td><td>Â¥ 2.536</td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1a515ae306bf7c3d",
        "value": 2.536,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "p.</td><td>Â¥ 1.723</td><td>B-2-7</td></tr><tr><td>AHICF</td><td>7747 JP</td><td>Asahi Intec</td><td>Â¥ 2.536</td><td>B-2-7</td></tr><tr><td>SMSZF</td><td>2175 JP</td><td>SMS</td><td>Â¥ 1.583</td><td>B-3",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "80596a33f01b28a4",
        "value": 1.583,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "sahi Intec</td><td>Â¥ 2.536</td><td>B-2-7</td></tr><tr><td>SMSZF</td><td>2175 JP</td><td>SMS</td><td>Â¥ 1.583</td><td>B-3-7</td></tr><tr><td>MTHRF</td><td>2413 JP</td><td>M3</td><td>Â¥ 2.186</td><td>C-2-",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "6459c4ad8adf4441",
        "value": 2.186,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "/td><td>SMS</td><td>Â¥ 1.583</td><td>B-3-7</td></tr><tr><td>MTHRF</td><td>2413 JP</td><td>M3</td><td>Â¥ 2.186</td><td>C-2-7</td></tr><tr><td>XEQNF</td><td>4480 JP</td><td>Medley</td><td>Â¥ 2.482</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "881d984661d1e95f",
        "value": 2.482,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "><td>M3</td><td>Â¥ 2.186</td><td>C-2-7</td></tr><tr><td>XEQNF</td><td>4480 JP</td><td>Medley</td><td>Â¥ 2.482</td><td>C-1-9</td></tr><tr><td>JMDCF</td><td>4483 JP</td><td>JMDC</td><td>Â¥ 4.162</td><td>C-",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d4b5d5a626a346c6",
        "value": 4.162,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "td>Medley</td><td>Â¥ 2.482</td><td>C-1-9</td></tr><tr><td>JMDCF</td><td>4483 JP</td><td>JMDC</td><td>Â¥ 4.162</td><td>C-1-7</td></tr><tr><td>SWGHF</td><td>4887 JP</td><td>Sawai Group HD</td><td>Â¥ 1.874<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "01ca244c28467d1a",
        "value": 1.874,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "/td><td>Â¥ 4.162</td><td>C-1-7</td></tr><tr><td>SWGHF</td><td>4887 JP</td><td>Sawai Group HD</td><td>Â¥ 1.874</td><td>C-1-7</td></tr><tr><td>PHCCF</td><td>6523 JP</td><td>PHC Holdings</td><td>Â¥ 987</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "cbfea77e8f6ff7f0",
        "value": 987.0,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "D</td><td>Â¥ 1.874</td><td>C-1-7</td></tr><tr><td>PHCCF</td><td>6523 JP</td><td>PHC Holdings</td><td>Â¥ 987</td><td>B-3-8</td></tr><tr><td>MEPDF</td><td>7459 JP</td><td>Medipal Holdings</td><td>Â¥ 2.614<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "c7281e04b028ccc4",
        "value": 2.614,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "/td><td>Â¥ 987</td><td>B-3-8</td></tr><tr><td>MEPDF</td><td>7459 JP</td><td>Medipal Holdings</td><td>Â¥ 2.614</td><td>B-3-7</td></tr><tr><td>AINPF</td><td>9627 JP</td><td>Ain Holdings</td><td>Â¥ 6.114</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d7dbb1a5a4ff3ecf",
        "value": 6.114,
        "unit": "Â¥",
        "metric_type": "currency",
        "context": "s</td><td>Â¥ 2.614</td><td>B-3-7</td></tr><tr><td>AINPF</td><td>9627 JP</td><td>Ain Holdings</td><td>Â¥ 6.114</td><td>B-3-7</td></tr><tr><td>ALPMY</td><td>ALPMY US</td><td>Astellas Pharma</td><td>$ 11.0",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "da754ba314a6f7b5",
        "value": 11.05,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>Â¥ 6.114</td><td>B-3-7</td></tr><tr><td>ALPMY</td><td>ALPMY US</td><td>Astellas Pharma</td><td>$ 11.05</td><td>B-2-7</td></tr><tr><td>DSNKY</td><td>DSNKY US</td><td>Daiichi Sankyo</td><td>$ 24.50",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "f6c45196b2b06af8",
        "value": 24.5,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 11.05</td><td>B-2-7</td></tr><tr><td>DSNKY</td><td>DSNKY US</td><td>Daiichi Sankyo</td><td>$ 24.50</td><td>C-1-7</td></tr><tr><td>FUJY</td><td>FUJY US</td><td>FUJIFILM Holdings</td><td>$ 11.9",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "61d6972ff5dedab8",
        "value": 11.99,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$ 24.50</td><td>C-1-7</td></tr><tr><td>FUJY</td><td>FUJY US</td><td>FUJIFILM Holdings</td><td>$ 11.99</td><td>B-2-7</td></tr><tr><td>OTSKY</td><td>OTSKY US</td><td>Otsuka Holdings</td><td>$ 26.6",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1e42cc76e88daf87",
        "value": 26.64,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$ 11.99</td><td>B-2-7</td></tr><tr><td>OTSKY</td><td>OTSKY US</td><td>Otsuka Holdings</td><td>$ 26.64</td><td>B-1-7</td></tr><tr><td>SGIOY</td><td>SGIOY US</td><td>Shionogi</td><td>$ 8.72</td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "2b42930b5ffb3f76",
        "value": 8.72,
        "unit": "$",
        "metric_type": "currency",
        "context": "ings</td><td>$ 26.64</td><td>B-1-7</td></tr><tr><td>SGIOY</td><td>SGIOY US</td><td>Shionogi</td><td>$ 8.72</td><td>B-1-7</td></tr><tr><td>TAK</td><td>TAK US</td><td>Takeda Pharm.</td><td>$ 14.97</td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "6909a2fa591e8e16",
        "value": 14.97,
        "unit": "$",
        "metric_type": "currency",
        "context": "nogi</td><td>$ 8.72</td><td>B-1-7</td></tr><tr><td>TAK</td><td>TAK US</td><td>Takeda Pharm.</td><td>$ 14.97</td><td>B-1-7</td></tr></table> Source:BofA Global Research ## Price objective basis & risk ",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "392f74e181559e96",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ", also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth rate 1.0% and tax rate 40%. Individual company FCF r",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "06c0309d91f3b7ab",
        "value": 0.055,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth rate 1.0% and tax rate 40%. Individual company FCF risk is reflected in the sto",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "63104771a703067a",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "P/B. Our DCF assumptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth rate 1.0% and tax rate 40%. Individual company FCF risk is reflected in the stock beta, which takes into a",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "3f0f781798b1cef8",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mptions are risk - free rate 1.5%, equity risk premium 5.5%, terminal growth rate 1.0% and tax rate 40%. Individual company FCF risk is reflected in the stock beta, which takes into account quantitati",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "cd89e46f8df449dc",
        "value": 0.051,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sted beta of 0.59 and base our price objective for the company on a stock beta of 0.65, and WACC of 5.1%. Our PO corresponds to a P/E of 22x our FY12/26 EPS forecast. Downside risks to our PO are a wo",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "d488ee7e259b9647",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "osts, based on a 20 - year earnings forecast. Our primary DCF assumptions are a risk - free rate of 1.0%, risk premium of 6.0%, WACC of 6.8%, and equity beta of 1.10. The beta is based on an assessmen",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "0fca34850f1c57dc",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "year earnings forecast. Our primary DCF assumptions are a risk - free rate of 1.0%, risk premium of 6.0%, WACC of 6.8%, and equity beta of 1.10. The beta is based on an assessment of the degree of ris",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "3d326999fc359f29",
        "value": 0.068,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "forecast. Our primary DCF assumptions are a risk - free rate of 1.0%, risk premium of 6.0%, WACC of 6.8%, and equity beta of 1.10. The beta is based on an assessment of the degree of risk to future ea",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "c870015444583b60",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "consideration other valuation metrics such as EV/EBITDA. DCF assumptions are a risk - free rate of 1.0%, an equity premium of 6.0%, and a perpetual growth rate of 1.0%. FCF risk is reflected in the eq",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "ff50f368d94dc94b",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ion metrics such as EV/EBITDA. DCF assumptions are a risk - free rate of 1.0%, an equity premium of 6.0%, and a perpetual growth rate of 1.0%. FCF risk is reflected in the equity beta, which considers",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "36a4ed77c5f440c9",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sumptions are a risk - free rate of 1.0%, an equity premium of 6.0%, and a perpetual growth rate of 1.0%. FCF risk is reflected in the equity beta, which considers quantitative risk derived from scena",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "af9381e62d045cf3",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent strategies. The equity beta of 1.04 is based on two - year adjusted Bloomberg data, and WACC of 6.5%. Our price objective corresponds to an EV/EBITDA of 19x FY3/27 forecasts. Downside risks to our",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "aa053902549d3dff",
        "value": 0.015,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d also taking into account valuations such as P/E and P/B. Our DCF assumptions are risk - free rate 1.5%,<ï½endâofâsentenceï½>",
        "provenance": {
          "page": 15
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 16,
      "tables_count": 0,
      "numerical_data_count": 230,
      "passages_count": 161,
      "entities_count": 20
    }
  }
}